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ABSTRACT 
 
The ABCB1 gene encodes P-glycoprotein, a transmembrane protein that regulates 
the efflux of drugs in the cells and may affect the response to antiretroviral drugs. 
ABCB1 polymorphisms affect the function or expression of P-gp. The 3435T 
allele has been associated with decreased protein production, but is in linkage 
disequilibrium with other polymorphisms. HIV is prevalent in Southern Africa, 
and characterization of ABCB1 variation may provide insight into its role in 
antiretroviral immune response. The aim was to determine if there was any 
association between ABCB1 variation, relative mRNA levels and immune 
response. Seven known polymorphisms were characterized for linkage 
disequilibrium and haplotype analysis, regions upstream of the gene were 
sequenced for bioinformatic analysis, the relative amounts of mRNA were 
determined, and CD4
+
 and viral load data was analyzed for association. 
Sequencing revealed six novel variations: T-137G, C-233T and G-298A 
upstream of exon 1, T108G and G153A in exon 2, and A111G in intron 26. The 
frequencies of the -129T (0.85), 1236T (0.70), 2677G (0.77), IVS 25+3050G 
(0.86), IVS 25+5231T (0.51), 3435C (0.88) and IVS 26+80T (0.89) 
polymorphisms were different and LD was lower compared to other populations. 
The haplotype frequencies were different to other populations and the genetic 
structure was probably a result of multiple recombination or mutation events. The 
viral load counts at the second measurement after baseline (time point 2) were 
significantly different from baseline for the 2677GG and 2677GA genotypes, and 
the -129T allele was associated with a lower proportional decrease in viral load at 
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the second measurement. The IVS 25+3050GG, 3435CC and IVS 26+80TT 
genotypes have been associated with lower mean relative mRNA levels. In 
conclusion, the genetic structure of the southern African populations is different 
from other populations and that genetic association and functional studies derived 
from other populations would be irrelevant in this population. A larger sample 
size and functional studies would be required to attempt to resolve the molecular 
mechanisms of the ABCB1 gene and to confirm the findings of association 
between ABCB1 polymorphisms and immune response. 
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CHAPTER 1: INTRODUCTION 
 
1.1 Pharmacogenetics 
 
Pharmacogenetics is the investigation of the relationship between genetic 
variation and individual differences in drug response. Although there are strict 
regulations for clinical trials that must be followed to ensure drugs are effective 
and safe, some individuals may have adverse reactions to the drugs, or the drugs 
may have no effect (Roses 2000a). Variation in genes encoding proteins, such as 
drug-metabolizing enzymes, transporters and receptors, influence the response of 
an individual to different drugs (Gwee et al. 2003). The goal of pharmacogenetics 
is to improve the understanding of how genetic variation can influence drug 
response, to ensure treatment is effective without the adverse side effects, and to 
find new methods of treating or preventing diseases (Schmith et al. 2003; Javitt 
and Hudson 2007; Marsh 2008; Löscher et al. 2009). 
 
Genetic variation is an important factor in individual response to certain drugs 
and their susceptibility to the toxicity of these drugs (Stanger et al. 2003; Martin 
et al. 2004). Knowing how the variation causes these changes and being able to 
determine individual variation will be important for individualizing medicine, 
based on the genetic make-up of an individual, and increasing the rate of drug 
development (Roses 2000b). 
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SNPs in the human population are of particular interest for studying human 
evolution, determining the mechanisms of maintaining genetic variability in the 
population and for identifying genes associated with complex diseases (Yu et al. 
2002). SNPs and other genetic factors provide information on how an individual 
responds to a pathologic disease and how drugs can be made to suit the 
individual. Genetic variation in drug-metabolizing enzymes, transporters, 
receptors and other genetic factors influence the response of an individual to 
different drugs (Gwee et al. 2003). 
 
The most common type of polymorphism (sequence variation) found in the 
genome are single nucleotide polymorphisms (SNPs), which are single base 
substitutions found between individuals. They are found on average every 500 
nucleotides in a genome (Van Tassell et al. 2008). Most polymorphisms found in 
the genome do not change the structure or function of the protein, but some do, 
through amino acid changes. SNPs are characterized according to their location 
and the effect they have on the expressed protein. Random SNPs are the most 
common and occur in introns of genes and between genes. Coding SNPs are 
found in the exons of genes and non-coding SNPs occur outside the coding 
region of a gene in the promoter or 5′ or 3′ untranslated regions (UTR). Many 
non-coding SNPs are also regulatory SNPs, which have a role in controlling the 
expression of genes and evolutionary change. Synonymous SNPs are found in 
exons and do not cause a change in the amino acid sequence. They usually occur 
at the third (wobble) position of the codon (Cargill et al. 1999; Collins et al. 
1999; Knight 2004). 
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Human genetics uses two approaches: one approach uses populations of 
individuals with a disease to determine genes that make those individuals more 
susceptible to that disease; the second approach uses DNA sequence databases to 
identify genes and gene families that can be screened for their possible role in a 
disease (Roses 2000b). 
 
Single genes involved in rare diseases include the cystic fibrosis gene (located on 
chromosome 7) and a gene on chromosome 4 that has been related to 
Huntington‟s disease. Variation in a number of genes has been associated with 
immune response: variation in the thiopurine methyltransferase gene (TPMT), 
has been associated with toxicity with azathiopurine drugs, variation in the 
Cytochrome P450 2D6 (CYP2D6) gene has been associated with the outcome of 
tamoxifen treatment in breast cancer (Marsh 2008), and variation in the 
Cytochrome 2C9 (CYT2C9) and vitamin K epoxide reductase complex subunit 1 
(VKORC1) genes have been associated with warfarin sensitivity or resistance 
(Javitt and Hudson 2007).   
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1.2 HIV and Antiretrovirals 
 
The Human Immunodeficiency Virus (HIV), a retrovirus, causes Acquired 
Immune Deficiency Syndrome (AIDS) by invading cells with CD4
+
 receptors, 
including macrophages and helper T cells. HIV encodes its own reverse 
transcriptase, which it uses to produce DNA from its RNA. The DNA is then 
incorporated into the genome of the infected cell, where it is replicated when the 
cell replicates its own DNA. The replicated viral DNA is then translated into viral 
proteins for viral assembly, followed by viral release and cell death (Lal et al. 
2005). 
 
Antiretroviral drugs consist of five groups: nucleoside (or nucleotide) reverse 
transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors 
(NNRTIs), integrase inhibitors, fusion inhibitors and protease inhibitors (PIs), 
which bind and inhibit the HIV proteins reverse transcriptase and protease. 
NRTIs, such as zidovudine (AZT), are compounds that bind the HIV reverse 
transcriptase at the substrate binding site and inhibit HIV replication. NNRTIs, 
such as nevirapine and efavirenz, bind the HIV reverse transcriptase at a non-
substrate binding site to inhibit HIV replication (Travel et al. 1999). PIs, such as 
ritonavir, nelfinavir and indinavir, prevent the cleavage of the GAG and GAG-
POL precursors of HIV protease to form functional proteins (including reverse 
transcriptase, integrase and protease), preventing HIV maturation (Flexner 1998; 
Travel et al. 1999; Dickinson et al. 2005; Pozio et al. 2005). Combining NRTIs, 
NNRTIs and PIs in antiretroviral treatment leads to the improved inhibition of 
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both HIV reverse transcriptase and HIV protease, thereby increasing CD4
+
 T cell 
count, decreasing of viral load and delaying disease progression (Henry et al. 
1998). Highly active antiretroviral therapy (HAART) is a combination therapy 
using at least three antiretroviral drugs: two NRTIs, one NRTI and one or two PIs 
(Van Heeswijk et al. 2002).   
 
HIV-1 protease is essential to the virus for its replication and the maturation of 
viral particles. Protease inhibitors prevent the post-translational cleavage of the 
long peptide precursors and thereby inhibit viral assembly (Dickinson et al. 2005; 
Pozio et al. 2005). The eleven current protease inhibitors are amprenavir, 
ritonavir, nelfinavir, darunavir, indinavir, saquinavir, lopinavir, norvir, 
atazanavir, fosamprenavir and tipranavir (UNAIDS 2008).  
 
The high mutation rate of the virus has necessitated the use of several drugs 
simultaneously to prevent drug resistance. The combination therapy has some 
disadvantages, such as the serious side effects, response rate, cost and the strict 
protocol that must be followed. Because of the disadvantages of combination 
therapy and the prevalence of HIV infections, other areas are being investigated 
in the fight against the AIDS pandemic (Lal et al. 2005). These include research 
into AIDS restricting genes and antiretroviral drug transporters. 
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1.3 ABCB1 and P-glycoprotein 
 
The multidrug resistance-1 gene (ABCB1 or MDR1) is the first of seven members 
of the ATP-binding cassette family, subfamily B. The gene was first identified in 
cancer cells that showed resistance to a variety of structurally unrelated drugs, 
and was therefore named multidrug resistance gene (Sukhai et al. 2000). It was 
observed that cancer chemotherapy failed due to overexpression of ABCB1 
(Labialle et al. 2002). 
 
The ABCB1 gene, which is located on chromosome 7q21.1, is approximately 210 
kilobases (kb) in size and is composed of a core promoter region preceeding 29 
exons (Bodor et al. 2005). ABCB1 homologs have been reported in a variety of 
organisms, including humans, fruit flies, yeast and some plants. A large number 
of single nucleotide polymorphisms (SNPs) has been found throughout the gene, 
in both coding and non-coding sequences (Schaeffeler et al. 2001). 
 
ABCB1 functions to regulate the movement of drugs, peptides and foreign 
substances (xenobiotics) in the cell. It does this by encoding P-glycoprotein, a 
170 kDa transmembrane transporter (Taniguchi et al. 2003; Tang et al. 2004), 
that acts as an efflux pump. The P-glycoprotein is a phosphorylated and N-
terminally glycosylated energy-dependant efflux pump made up of 1280 amino 
acids (Schwab et al. 2003). P-glycoprotein is composed of two homologous, 
symmetrical domains, each domain comprising six transmembrane regions and 
an ATP-binding motif. ATP hydrolysis is performed to provide the energy 
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required to actively pump a variety of hydrophobic, amphipathic compounds 
against a steep gradient, from inside the cell to the extracellular domain (Kim et 
al. 2001). Membrane transporters play a role in providing drug targets and 
physiological processes, such as maintaining homeostasis in cells and organisms. 
They all have similar secondary structures, multiple membrane-spanning regions 
separated by intracellular and extracellular loops (Leabman et al. 2003). 
 
The substrates that bind to the transporter have a broad specificity (Bodor et al. 
2005) and include hormones, plant-derived chemicals (Stenger et al. 2003) and 
more than 50 commonly used drugs, including HIV-1 protease inhibitors. The 
affinity with which the substrates bind P-glycoprotein depends on their hydrogen 
bonding and their affinity for lipids (Soranzo et al. 2004; Zhu et al. 2004). The 
mechanisms by which P-glycoprotein acts on HIV immune recovery are unclear, 
although a few suggestions have been made (Owen et al. 2005). There maybe a 
relationship between P-gp and the expression of HIV-relevant proteins that affect 
the cell‟s susceptibility to infection (Owen et al. 2004), P-gp might act directly on 
the virus by affecting viral replication or infection (Lee et al. 2000), or it might 
act on other proteins and cholesterol (Xiao et al. 1998; Speck et al. 2002).  
 
P-glycoprotein is expressed in a variety of tissues, such as the kidney, liver, small 
intestine and brain, and cells of the immune system, including mature 
macrophages, natural killer cells, antigen presenting dendritic cells and T and B 
lymphocytes. The function of the protein is to protect the body from toxins by 
excreting them into the bile, urine and intestinal lumen, to regulate oral 
 21 
absorption of drugs, to help in the defence against viral infections and to play a 
role in steroid metabolism (Hoffmeyer et al. 2000; Schaeffeler et al. 2001). 
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1.4 ABCB1 Promoter Region 
 
The ABCB1 gene has two promoters and two transcriptional start sites. The first 
promoter, located in exon 1 -434 to +1 in relation to exon 1b, does not have a 
TATA box, is undefined and believed to be cryptic (Cornwell et al.1993; Scotto 
et al. 2003; Takane et al. 2004). Cornwell et al (1993) reported that the region did 
not have a high CpG content, whereas Takane et al. (2004) reported that the 
region is CpG-rich. CpG sites in promoter regions are sites for DNA methylation, 
which is the most common form of DNA modification in eukaryotes (Takane et 
al. 2004). Hypomethylation of the ABCB1 gene results in elevated gene 
expression (Takane et al. 2004).  
 
The promoter is regulated by an initiator element (Scotto et al. 2003). A 13 bp 
region surrounding the proximal initiator element (-6 to +7) has been related to 
accurate initiation in vitro and the sequence downstream of the initiator site has 
been shown to be important in the efficiency of promoter activity (Cornwell et 
al.1993). A G-rich region in the proximal promoter (-121 to -88) has been shown 
to bind to transcriptional activators and repressors (Cornwell et al.1993). 
 
The second promoter, which is in exon 2, drives gene expression in both normal 
and tumour tissues (Cornwell et al.1993; Wang et al. 2006). The translational 
start site is situated in exon 3. As the translational start site occurs in exon 3, 
exons 1 and 2 are often combined as exons 1a and 1b, making exon 3 also known 
as exon 2 (Wang et al. 2006). 
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This upstream region contains a Y-box or inverted CCAAT-box (-79 to -75), 
which is a binding site for the transcription factor NE-Y, and a GC-box (-56 to -
43), which is a binding site for the transcription factors Sp1 and Sp3. Both these 
elements are required for efficient transcriptional regulation and are commonly 
found in TATA less promoters (Taniguchi et al. 2003; Scotto et al. 2003; Takane 
et al. 2004). The promoter region also contains an inverted multiple start site 
element downstream 1 or iMED1 (-105 to -100), which has been associated with 
the activation of ABCB1 in drug-resistant cells and transcription is decreased by 
60% when iMED1 is functionally disrupted (Scotto et al. 2003; Labialle et al. 
2002). Transcription of the ABCB1 gene is also repressed by the binding of p53 
to any of the numerous sites (Scotto et al. 2003) (Figure 1). 
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Figure 1: The location of regulatory elements within the ABCB1 promoter region 
upstream of the transcriptional start site in exon 1b (adapted from Taniguchi et al. 
2003). 
 
Numerous elements have been identified as regulators of ABCB1 transcription. 
Variation that interferes with the functioning of these elements or that generates 
other regulatory elements can play a role in the regulation of ABCB1 gene 
expression (Wang et al. 2006).  
 
Mutations in the -110 G-box (-110 to -103) in the proximal promoter region have 
been shown to increase promoter activity and inhibit the formation of a specific 
nuclear protein complex, suggesting that the region normally functions as a 
transcriptional repressor binding site (Cornwell et al.1993). Mutation or deletion 
of the -50 G-box (-61 to -43) decreases promoter activity, suggesting that the site 
normally enhances promoter activity, and inhibits the binding of the transcription 
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factor Sp1 to the -50 G-box, which is required for efficient promoter activity 
(Cornwell et al.1993). Mutations in the ABCB1 promoter region, especially in the 
Y-box, have been shown to reduce the activity of the promoter in some drug-
sensitive and drug-resistant human cell lines (Goldsmith et al. 1993). 
 
Two specific SNPs (T-129C and A-41G) in the promoter region affect promoter 
activity and are associated with differential gene expression. In the presence of 
the major alleles (-129T and -41A) these SNPs have been associated with a 
decrease in promoter activity, but in the presence of the minor allele (-129C and -
41G) the SNPs have been associated with an increase in promoter activity 
(Labialle et al. 2002; Scotto 2003; Taniguchi et al. 2003; Wang et al. 2006). 
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1.5 ABCB1 variation and pharmacogenetics 
 
Variation in ABCB1 results in differences in P-glycoprotein expression in normal 
tissues, leading to inter-individual differences in drug response. Site-directed 
mutagenesis studies have been performed to introduce nucleotide changes in 
highly conserved regions of ABCB1, resulting in profound changes in P-
glycoprotein expression and function (Pauli-Magnus and Kroetz 2004). Variation 
in the ABCB1 gene has been associated with a variety of disorders, such as renal 
cell carcinoma, Parkinson‟s disease, inflammatory bowel diseases (e.g. ulcerative 
colitis and Crohn‟s disease), there is some debate as to the association in epilepsy 
(Stanger et al. 2003; Martin et al. 2004; Leschziner et al. 2007), and there has 
also been associated with CD4
+
 cell recovery with antiretroviral therapy (Stanger 
et al. 2003; Martin et al. 2004). 
 
To date, about 600 polymorphic sites have been identified in the almost 210 kb 
ABCB1 gene. Of these polymorphic sites, the majority are found in the non-
coding regions and only about 47 are found in exons. The most commonly 
studied SNP is the synonymous C3435T transition in exon 26 
(http://www.ensembl.org, ID: ENSG00000085563), which has associated with a 
change in the expression and function of P-glycoprotein. The SNP results in a 
synonymous substitution in a codon which codes for isoleucine in P-glycoprotein, 
which results in a decrease in the expression of the protein. A large number of 
genotype-phenotype studies have been performed and many have yielded 
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conflicting results, for which there are a number of reasons, and the molecular 
basis of the ABCB1 SNP at 3435 is still not well understood.  
 
The ABCB1 3435TT genotype has been shown to result in a conserved silent 
(“wobble”) polymorphism and corresponds to a decreased level of P-glycoprotein 
expression, while the 3435CC and 3435CT genotypes show comparatively higher 
and intermediate levels of P-glycoprotein expression, respectively (Hoffmeyer et 
al. 2000; Kim et al. 2001; Stanger et al. 2003). Hoffmeyer et al. (2000) concluded 
that the synonymous C3435T polymorphism in exon 26 was the causal site for 
functional variation, since the TT genotype corresponded with the lowest P-
glycoprotein levels, whereas the CC genotype correlated with the highest P-
glycoprotein levels. Decreased expression of P-glycoprotein causes less of the 
drugs to be pumped out of the cell or tissue (Fellay et al. 2002) thus, allows the 
drug to exert its effects for a long time at a concentration that inhibits viral 
replication.  
 
Many studies have focused solely on this one polymorphic site, but Soranzo et al. 
(2004) questioned the importance of this site acting alone. They found three 
intronic polymorphisms with high levels of linkage disequilibrium with the 3435 
locus, IVS 25+G3050T and IVS 25+T5231C in intron 25, and IVS 26+T80C in 
intron 26 and suggested that the C3435T site was probably not solely responsible 
for the functional variation, but that a number of linked polymorphic sites were 
probably the cause of the differences seen in the expression levels of P-
glycoprotein.  
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Strong linkage disequilibrium has been found within the entire ABCB1 gene, but 
especially between the SNP in exon 26 and certain other SNPs (G2677T in exon 
21, G3050T and T5231C in intron 25, T80C in intron 26), making it difficult to 
determine which SNP is responsible for the change in protein expression. The 
SNP in exon 21 causes an amino acid change from alanine to serine at position 
893 in the peptide. The serine variant has been shown to enhance the 
transportation function of P-glycoprotein when compared to the alanine variant 
(Kim et al. 2001). Both SNPs in exons 12 and 26 are synonymous, meaning that 
they do not change the encoded amino acids glycine and isoleucine, respectively 
(Taniguchi et al. 2003). The 2677T and 3435T alleles form the ABCB1*2 
haplotype (Kroetz et al. 2003). A number of haplotypes, groups of linked alleles 
that are inherited as a unit, have been found involving polymorphic sites within 
the ABCB1 gene. The observed effects may be due to a single SNP (G2677T/A or 
C3435T) or a haplotype involving these SNPs (Allabi et al. 2005; Ardlie et al. 
2002, Ding et al. 2003; Shifman et al. 2003; Bleiber et al. 2004; Takane et al. 
2004). 
 
Leschziner et al. (2007) genotyped three ABCB1 polymorphisms (C1236T, 
G2677T/A and C3435T) in epilepsy patients and found no association with any 
of the SNPs and multidrug resistance. They suggested that the C3435T 
polymorphisms may not be the functional variant, but rather that it is in linkage 
disequilibrium, non-random association, with another site, which may be the 
functiona variant, and that gene-wide tagging might reveal the true finctional 
variant. The role of the variation in ABCB1 in immune response is still unknown 
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and to facilitate the understanding of how variation is associated with immune 
response, the genetic structure and patterns of linkage disequilibrium are required 
(Leschziner et al. 2006). The use of tagged SNPs to reduce the number of sites 
required for genotyping will only be useful in populations with high levels of 
linkage disequilibrium, such as Caucasian populations, but might not be useful in 
populations with low levels of linkage disequilibrium, such as African 
populations (Leschziner et al. 2006). 
 
A change in the tertiary conformation of P-glycoprotein could be the basis for the 
reduced functionality. This could be due to shortened mRNA molecules caused 
by the inactivation of splice donor sites by a synonymous polymorphism, which 
results in a premature stop codon or exon splicing (Kimchi-Sarfaty et al. 2007). 
Although the 1236T and 3435T SNPs alleles are synonymous substitutions, they 
have been shown to result in a change in the mRNA structure, whereas the 2677T 
nonsynonymous substitution does not (Wang and Sadée 2006). In vitro 
transfections showed that only the 3435T allele decreased mRNA levels by 
affecting mRNA stability.  
 
Wang et al. (2005) found an association between the 3435C allele and higher 
mRNA expression levels, while the 3435T allele was associated with a decrease 
in mRNA stability, possibly due to effects on the secondary structure of the 
mRNA molecule (Moriya et al. 2002; Nakamura et al. 2002). 
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Single base sustitutions can cause differences in mRNA folding, which can 
influence splicing, processing or transcriptional regulation of the resulting 
protein. Reports by Kimchi-Sarfaty et al. (2007) have shown that it may not be 
the presence of the G2677T polymorphism that is causal, but the presence of the 
C3435T polymorphism in combination with one or two other SNPs due to the 
observation of different tertiary structures between the wild-type and haplotype 
P-glycoprotein (C1236T-G2677T-C3435T).  
 
In individuals suffering from the diseases associated with variation in ABCB1 
(carcinomas, Parkinson‟s disease, inflammatory bowel diseases and epilepsy), the 
3435T allele was found to present at a higher frequency than the 3435C allele. 
The 3435T allele has also been associated with a decrease in drugs being pumped 
out of CD4
+
 cells and shown to increase the recovery of these cells during 
antiretroviral therapy (Stanger et al. 2003) and reduce susceptibility to HIV 
infection (Schaeffeler et al. 2001). Antiretroviral therapy (ART) involves the use 
of a variety of drugs and drug classes to combat the virus. The use of multiple 
drugs results in different drug-host and drug-drug interactions, to which genetic 
variations also contribute (Martin et al. 2004). HIV-1 infected individuals have 
shown significant variation in the effect of antiretroviral therapy, their plasma 
drug concentrations, the rate of immune recovery and their response to toxins. In 
a population of HIV positive individuals treated with antiretrovirals, such as 
efavirenz and nelfinavir, those with the 3435TT genotype demonstrated better 
CD4
+
 T cell recovery and decreased viral load compared to those with the 
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3435CC genotype (Telenti et al. 2002; Nasi et al. 2003), further supporting a role 
for the C3435T in drug response. 
 
Transporters also play a role in the protection of the host from viral infections.  
P-glycoprotein has been associated with the glycolipid-rich membrane domains, 
known as lipid rafts, which are sites for viral fusion and release. P-glycoprotein 
overexpression affects viral fusion and release, resulting in decreased 
susceptibility of CD4
+
 cells to HIV infection, thus the reduction in P-glycoprotein 
expression that has been attributed to the 3435TT genotype (Fellay et al. 2002; 
Hulgan et al. 2003; Bleiber et al. 2004; Tang et al. 2004) could actually be 
associated with increased risk of infection. There have been suggestions that the 
C3435T polymorphic site may not be the causal site, but that another site, 
undetected as a result of linkage disequilibrium, may be the cause of the 
functional variation. Three intronic sites have been identified to have strong 
linkage disequilibrium with the C3435T site in Europeans and may be additional 
candidates for the influence of P-glycoprotein expression (Soranzo et al. 2004). 
 
The polymorphism or combination of polymorphisms responsible for the 
observed functional variation, as well as the molecular basis of the ABCB1 gene 
are still unknown. Linkage disequilibrium between SNPs makes it difficult to 
determine which SNP is responsible for the observed phenomenon, as the SNPs 
cannot be analysed seperately. 
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1.6 ABCB1 and Antiretrovirals 
 
Many human genes and other factors, such as sex, age and environmental 
determinants, influence the progression to AIDS and the response to antiretroviral 
therapy. The use of antiretrovirals, such as NNRTIs can result in adverse effects 
or cumulative toxicity, which can be life-threatening (Wilson et al. 2001; Telenti 
et al. 2002). Nevirapine and efavirenz have been associated with hepatotoxicity in 
patients with high and low CD4
+
 T cell counts, respectively (Ritchie et al. 2006). 
It is therefore important to understand the mechanisms of drug toxicity in order to 
minimize the adverse effects and increase the efficacy of antiretroviral therapy, or 
to find drugs that do not have a toxic effect (Fellay et al. 2002).  
 
There are differences between populations and also between individuals, which 
might affect the efficacy or toxicity of the drugs. These differences include 
variation in metabolism and transport of drugs. The best time to start therapy as 
well as the most effective drug combination might be based on a particular 
genotypic profile (Telenti et al. 2002; Ritchie et al. 2006). Genetic tests might be 
used to predict an individual‟s response to specific drugs and thereby allow the 
drug combination to be tailored to the individual‟s genetic makeup (Wilson et al. 
2001). 
 
Variation in the ABCB1 gene results in different concentrations of protease 
inhibitors and can be used to predict the rate of recovery of the immune system 
after the start of antiretroviral therapy, using increased CD4
+
 T cells as an 
 33 
indication (Telenti et al. 2002). Although NNRTIs are not substrates of P-
glycoprotein, there have been suggestions that P-glycoprotein is involved in the 
disposition of nevirapine and efavirenz, but these findings remain controversial. 
P-glycoprotein expression has been linked to intracellular nevirapine 
concentrations (Störmer et al. 2002) and the inhibition of intestinal P-
glycoprotein is predicted to increase the oral bioavailability and decrease the 
clearance of protease inhibitors (von Heeswijk et al. 2002).  
 
It may be that P-glycoprotein can alter the clinical course of HIV infection in a 
mechanism, independent of its role in drug transportation (Winzer et al. 2005). 
Overexpression of P-glycoprotein in CD4
+
 T cells has been shown to result in the 
inhibition of HIV replication, increased efficacy of antiretrovirals and decreased 
viral fusion and release (Fellay et al. 2002). During the progression of the HIV 
disease CD4
+
 T cell numbers decrease primarily as a result of an increase in cell 
loss, rather than a decrease in cell production. The CD4
+
 T cell turnover may be 
influenced by P-glycoprotein expression (Fellay et al. 2002; Haas et al. 2003).  
 
The 3435T allele has been associated with a decreased risk of hepatotoxicity with 
NNRTI-containing antiretroviral drug regimes and a more favourable virological 
response to antiretroviral drug regimes that include efavirenz (Ritchie et al. 
2006). The 3435CC genotype has been associated with a decreased response to 
combination antiretroviral therapy (Fellay et al. 2002) as well as earlier 
virological failure with the use of protease inhibitors (Brumme et al. 2003). The 
3435TT genotype has been associated with an increase in CD4
+
 T cells in 
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patients receiving antiretroviral therapy (Haas et al. 2003) as well as lower 
plasma drug concentrations of nelfinavir and efavirenz (Fellay et al. 2002).  
 
In 149 drug-naïve HIV positive patients no evidence of influence of the ABCB1 
genotype on the efficacy of antiretrovirals was found (Nasi et al. 2003). In 411 
subjects no correlation was found between ABCB1 expression and permissiveness 
or HIV infection, and no modification of disease progression by ABCB1 
genotypes was reported (Bleiber et al. 2004). Winzer et al. (2005) reported no 
significant difference in the response (virological or immunological) of 72 HIV 
positive patients with respect to the 3435 or 2677 genotypes, or the 2677- 3435 
haplotype. 
 
A correlation has been reported between the expression of ABCB1, P-
glycoprotein and plasma drug concentrations (Fellay et al. 2002). There was an 
immunological benefit in the presence of the 3435TT genotype and lower levels 
of P-glycoprotein (measured by flow cytometry), presumably due to the enhanced 
presence of antiretroviral drugs in cells infected by HIV-1 (Fellay et al. 2002). 
This evidence shows a potential molecular basis for interindividual differences in 
the rate of CD4
+
 T cell recovery with antiretroviral therapy, but there is still 
controversy surrounding the association between ABCB1 variation, P-
glycoprotein expression and function and plasma drug concentrations (Fellay et 
al. 2002; Winzer et al. 2005). 
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1.7 Population Differences 
 
Studies on the variation of the ABCB1 gene and the effects of P-glycoprotein 
have been done for Europeans, Asians, Americans, African Americans and West 
Africans, but not for South Africans, where HIV is highly prevalent. The 
frequency of common mutations and the possibility of population-specific SNPs 
both play a role in the drug response and success of drug therapy in infected 
individuals. The SNPs in exons 12, 21 and 26 have been found in all populations, 
but the frequencies at which they occur are different (Hoffmeyer et al. 2000; Kim 
et al. 2001; Schaeffeler et al. 2001; Fellay et al. 2002; Tang et al. 2002; Telenti et 
al. 2002; Gwee et al. 2003; Tang et al. 2004) as shown by the frequencies of the 
3435T allele of approximately 0.5 in Caucasians, 0.4 to 0.6 in Asians, and 
approximately 0.8 in Africans. When considering the SNPs in exon 12, 21 and 
26, different haplotypes are observed in different populations (Schaeffeler et al. 
2001; Tang et al. 2002; Tang et al. 2004; Zhu et al. 2004).  
 
In the West African population the frequency of the 3435C allele was found to be 
much higher frequency than in any other population, possibly due to natural 
selection against inflammatory bowel diseases, which is decreased in the 
presence of the 3435C allele (Schaeffeler et al. 2001). 
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1.8 African Origin 
 
There are two major hypotheses for the origin of modern humans. The first is the 
multiregional hypothesis, which suggests that modern humans evolved from 
more primitive forms over a period of a million years in different areas of the 
world. The second is the African replacement hypothesis, which suggests that 
modern humans originated in Africa and migrated throughout the world to 
replace the primitive human forms completely (Jorde et al. 1998; Reed and 
Tishkoff 2006). However, the high level of diversity found in Africans gives 
more support to the second hypothesis that modern humans first arose in Africa 
and then colonized other parts of the world.  
 
Variation in mitochondrial and nuclear DNA has shown the African populations 
to be the most variable and genetically diverse of all populations. Mitochondrial 
DNA and Y-chromosome haplotype have also shown all non-African lineages 
have a sub-set of the genetic diversity found in Africans, possibly due to genetic 
bottlenecks that occurred during the migration out of east Africa. Mitochondrial 
DNA and Y-chromosome haplotype lineages provided a model for the 3 main 
lineages that migrated within Africa. The first lineage (L1) is thought to be the 
most ancient and is present in the San population (South Africa) and the Biaka 
Pygmies (Central African Republic), the two most genetically diverse 
populations in Africa. The second lineage (L2) is present in the Mbuti Pygmies 
(Democratic Republic of Congo) and in the West African Bantu-speaking 
populations. The third lineage (L3) is widely distributed throughout East Africa 
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and is rare in the sub-Saharan region of Africa (Jorde et al. 1998; Tishkoff and 
Williams 2002; Yu et al. 2002; Watkins et al. 2003; Reed and Tishkoff 2006; 
Tishkoff et al. 2009). South Africa‟s population comprises mostly groups that are 
off shots of the Bantu population which fall under the bigger Niger-Congo group 
(Tishkoff et al. 2009). 
 
The Bantu expansion, migration and spread, occurred towards the south and east 
around 3,000 to 5,000 years ago from West Africa in the region of present day 
Nigeria and Cameroon into sub-Saharan Africa in two directions (Guthrie 1962; 
Phillipson 1993). The south western expansion followed a mostly coastal and 
ravine route, whereas the eastern expansion involved the movement and 
settlement of farmers in present day Uganda. From there, the Great Lake region, 
the expansion continued in two waves. The one wave moved south along the 
coast, while the other moved south through eastern Zimbabwe (Philipson 1993; 
Newman 1995; Beleza et al. 2005; Reed and Tishkoff 2006).  
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Figure 2: Diagram of the east and west Bantu migrations from West Africa into 
southern Africa (based on data from Beleza et al. 2005 and Reed and Tishkoff 
2006). 
 
Bantu speakers can be broadly classified on linguistic grounds. The Western 
Bantu languages are older and more diverse, whereas the Eastern Bantu 
languages are more recently derived (Nurse 1982; Vansina 1984). The East Bantu 
languages include a Sotho/Tswana language group (Southern Sotho, Northern 
Original 
Bantu 
Homeland 
East Bantu 
Migrations 
West Bantu 
Migrations 
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Sotho or Pedi, and Tswana), an Nguni language group (Zulu, Xhosa and Tonga 
or Shangaan) or Venda (Lane et al. 2002). There are about 400 Bantu languages, 
spoken by people in sub-Saharan Africa (Greenberg 1963; Guthrie 1962) and of 
the 11 official languages in South Africa, nine are Bantu languages. According to 
the National Census of 2001 the language distribution across South Africa is as 
follows: Zulu (23.8 %), Xhosa (17.6 %), Pedi (9.4 %), Tswana (8.2 %), Southern 
Sotho (7.9 %), Tsonga (4.4 %), Swati (2.7 %), Venda (2.3 %) and Ndebele 
(1.6%). The remaining 22.1 % of South Africans speak European languages 
(English and Afrikaans). 
 
South Africa has experienced an increase in the movement of people from rural 
to urban areas, often creating novel urban communities. This results in the mixing 
of different ethnic populations and alters of gene frequencies in these populations 
(Lane et al. 2002). The genetic structure of seven South African Bantu speaking 
groups showed that the seven groups shared 99% of their genetic variation, based 
on autosomal and Y-chromosome haplotype markers (Lane et al. 2002). This 
showed that although there had been a development of different languages, the 
different groups had all come from a common ancestor and the separation, during 
which the languages developed, had not been for a very long time. 
 
The demographics of human history are complex, due to populations migrating 
out of ancestral Africa into new regions, where they experienced isolation, 
migration, expansion or bottlenecks, all of which influence the genetic 
cmposition of the population (Ardlie et al. 2002). African populations show 
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tremendous diversity in the more than 2,000 distinct ethnic groups. The sub-
Saharan populations show an especially distinct difference in linkage 
disequilibrium patterns as opposed to non-African populations. They have more 
haplotypes and lower levels of linkage disequilibrium between alleles. Their high 
level of genetic variation and their demographic history make African 
populations useful for fine-mapping complex diseases (Jorde et al. 1998; Tishkoff 
et al. 2002; Reed and Tiahkoff 2006; Tishkoff et al. 2009). The multiple types of 
genetic systems (autosomal, mitochondrial and Y-chromosomal DNA) have 
shown that there is more genetic diversity in Africans than in Europeans or 
Asians and that Africans have the largest total number of alleles as well as the 
largest number of unique alleles (Jorde et al. 1998). 
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1.9 HIV/AIDS in South Africa 
 
At the end of 2009 it was estimated that 33.3 million people were living with 
HIV globally and that during that year approximately 2.6 million new HIV 
infections occurred with 1.8 million people dying of AIDS-related illnesses. It 
was estimated that 34% of people living with HIV were from ten countries in 
southern Africa, and that these ten countries counted for 31% of new infection 
and 34% of AIDS-related deaths that year. In sub-Saharan Africa 22.5 million 
people were estimates to be living with HIV (+/- 5.6 million in South Africa) and 
1.8 million new infections (+/- 1.5 million in South Africa) and 1.3 million 
AIDS-related deaths (+/- 310,000 in South Africa) occurred in 2009 (UNAIDS 
2010 Global Report).  
 
Based on the South African National HIV Survey 2008 (Shisana et al. 2009), 
which was a population-based household survey involving almost 49 million 
individuals over the age of 2 years, the HIV prevalence in South Africa is 
estimated to affect 10.9 % of the population (5.2 million people), compared to the 
11.4 % in 2002 and 10.8 % in 2005. KwaZulu Natal has the highest provincial 
estimated HIV prevalence (15.8 %), Gauteng is fifth on the list (10.3 %) and the 
Western Cape has the lowest estimated HIV prevalence (3.8 %). 
 
The interpretation of the prevalence data has become increasingly complex, as 
there is an increase in the access to antiretroviral therapy, which increases the 
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prevalence of HIV, as HIV-related deaths are reduced and more people are aware 
of their HIV status (Shisana et al. 2009).  
 
South Africa has the world‟s largest antiretroviral therapy program, but it also has 
the largest epidemic and access to treatment could be better. At the end of 2009 it 
was estimated that only 970,000 of HIV-infected individuals (17%) were 
receiving treatment. This was due to the delay and slow pace of treatment 
delivery, as well as a doubt in the efficacy of the drugs by many South Africans 
(WHO 2008; UNAIDS 2010 Global Report). There have been improvements in 
treatment delivery recently, but the cost remains problematic.  
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1.10 Aim 
 
Previous work involved genotyping the ABCB1 IVS 25+ G3050T and IVS 
25+T5231C SNPs in the southern African Bantu population, revealing different 
frequencies from values reported for other populations (Taniguchi et al. 2003; 
Soranzo et al. 2004). A region containing the C3435T and IVS 26+T80C 
polymorphic sites was sequenced in seventeen samples to determine the variation 
in this region. The allele frequencies for the C3435T and IVS 26+T80C SNPs 
were determined and novel variation was found. The frequency of the 3050T, 
3435T and 80C alleles were lower than those recorded for a European population. 
The frequency of the 5231C allele was approximately the same as that in the 
European population (Taniguchi et al. 2003; Soranzo et al. 2004). The 3435C 
allele frequency in the South African population sample was compared with 
frequencies found in other populations. It is clear that the European populations 
have the lowest 3435C allele frequency and the African populations have the 
highest 3435C allele frequency.  
 
Nineteen samples from the general population samples were successfully 
sequenced for the 5′ upstream untranslated region, revealing one a novel 
polymorphism. The number of samples sequences and genotypes is small and a 
greater sample number would produce more reliable data. 
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Variation in the human genome can have an effect on drug interactions and drug 
response, where the resonse to an ordinary drug can be an advese reaction or a 
lack of response altogether. The variation in these genes and their effect on 
antiretroviral drugs needs to be examined in the black South African population, 
where a high prevalence of HIV and an increasing availability of treatment mean 
that research in this field is essential. 
 
Pharmacogenetics can tailor the treatment to the genotypes of an individual. This 
may not be possible in the South African health care system, but there may be 
specific genotypes that are present in this population, either specific variation or 
different frequencies, that would alter the drug response to that seen in other 
populations. There is a need to understand the interactions between genetic 
factors and drug response, so that recommendations can be made for drug dosage 
and combination, to ensure the highest efficacy and lowest toxicity of 
antiretroviral drugs in the South African population. 
 
The aim of the project was to characterize variation in ABCB1 in the black South 
African population and to determine if any association could be found between 
that variation and immune response. 
 
To achieve this aim additional DNA samples were collected and the identified 
SNPs genotyped, followed by an analysis to estimate linkage disequilibrium and 
infer haplotypes. RNA was obtained during the last sample collection, in order to 
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obtain relative mRNA level data. CD4
+
 T cell count and viral load data was 
obtained for patients sampled at the Themba Lethu clinic. 
 
Two sets of association studies were performed: The first tested the association 
between SNPs or sets of SNPs and relative mRNA level data to determine if there 
was any association between variation in the gene and variation in expression 
levels. The second tested the association between SNPs or sets of SNPs and the 
relative change in CD4
+
 T cell count and viral load between the different time 
intervals, to determine any association between variation in the gene and immune 
response. 
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CHAPTER 2: MATERIALS & METHODS 
  
2.1 Samples 
 
Genomic DNA was obtained from a variety of sources for a broad study to 
characterize variation in genes involved in different aspects of HIV infection, 
including HIV drug metabolism and transportation in Bantu-speaking individuals 
living in the Johannesburg area. The sources of genomic DNA were whole blood 
collections from individuals from the university community and HIV clinics, and 
genomic DNA from the HIVNET 028 provided by Dr. Clive Gray. 
 
The initial collection of whole blood for DNA extraction comprised 42 volunteer 
staff and students recruited from the University of the Witwatersrand, who were 
chosen as Bantu-speakers and whose HIV status was unknown (labelled General 
Population).  
 
Numerous whole blood collections at HIV clinics over a number of years resulted 
in genomic DNA from 105 individuals from the Infectious Disease Clinic at 
Johannesburg Hospital, 94 individuals from the Themba Lethu Clinic at the 
Helen Joseph Hospital in 2006, and 104 individuals from the Themba Lethu 
Clinic at the Helen Joseph Hospital in Johannesburg. Patients were approached to 
volunteer for the study, based on language and being HIV positive. The Themba 
Lethu clinic was chosen because of their extensive database of clinical data, 
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which was accessed at a later stage of the study, and the willingness of patients to 
participate in studies.  
 
The whole blood from the 2009 collection at the Themba Lethu Clinic at the 
Helen Joseph Hospital was also used for the RNA extractions. 
 
Individuals were chosen for blood collection based on language, as the study was 
to focus on Bantu-speakers. All samples were obtained under informed consent 
(Ethics consent forms, permission letter from the Helen Joseph Hospital, patient 
information, questionnaires and consent forms for the 2006 and 2009 collections 
are given in Appendices IV, V and VI). From the Patient Questionnaire we were 
able to determine the place of birth and home language of the subject, parents and 
grandparents. The blood was drawn by a phlebotomist into EDTA-coated tubs for 
DNA and RNA extractions. 
 
The Patient Questionnaires revealed that all nine South African languages were 
represented in the individuals sampled (Table 1). In the group, 67 % of the 
subjects reporting a single language in 3 generations, 30 % reported more than 
one language (most of whom were born in Gauteng), and 3 % did not know what 
languages were spoken by their relatives. The concentrations of the previously 
collected DNA samples were determined using the NanoDrop
®
 ND-1000 version 
3.3 spectrophotometer. 
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Table 1: Frequency of the nine Bantu languages found in the samples collected 
from the Infectious Disease Clinic at Johannesburg Hospital, Themba Lethu 
Clinic at the Helen Joseph Hospital and the University of the Witwatersrand 
community. 
 
Bantu Language Frequency 
Zulu 0.41 
Tswana 0.13 
Xhosa 0.12 
Sotho 0.11 
Pedi 0.08 
Tsonga 0.06 
Ndebele 0.05 
Swati 0.02 
Venda 0.02 
 
 
Genomic DNA was also provided by Dr. Clive Gray from 64 recently HIV-1-
infected individuals within approximately 2 years of seroconversion as part of the 
HIVNET 028 study from five clinical sites in southern Africa: Johannesburg 
(n=9) and Durban (n=21), South Africa; Lusaka, Zambia (n=18); Harare, 
Zimbabwe (n=6) and Blantyre, Malawi (n=10). The concentration of the 
HIVNET samples is known to be 20 ng/μl (Morris et al. 2002). 
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2.2 DNA and RNA Extractions from Whole Blood 
 
The whole blood from each collection was used for DNA extraction and the 
whole blood from the last collection was also used for RNA extraction. 
 
The QIAGEN QIAamp
®
 (Germantown, USA) DNA Blood Mini Kit was used to 
extract genomic DNA from the leukocyte-rich buffy coat of whole blood 
obtained from the patients according to the manufaturer‟s instructions (Appendix 
I). The DNA was electrophoresed on a 0.8 % agarose gel in the presence of 
ethidium bromide to check for integrity and stored at -20
O
C. 
 
TRIzol LS was used to extract whole RNA from the blood obtained from the 
patients (Appendix I). The whole procedure was performed in a fume hood 
cabinet using RNase-free plastic- and glassware, and RNaseAway
®
 to avoid RNA 
degradation. The RNA solution was aliquoted into amounts of 20 μl and stored at 
-70
O
C. After the extraction, 10 μl of RNA was loaded on to a 1 % agarose gel to 
determine the presence and quality of RNA. 
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2.3 DNA Sequencing 
 
Sequencing was performed to characterize the variation in the upstream 
untranslated region, using randomly selected DNA samples. The 5′ upstream 
untranslated region from exon 1 was chosen, as this region contains regulatory 
elements and may provide insight into regulation in gene transcription. The 5′ 
upstream untranslated region from exon 3 was also chosen for sequencing, as 
transcription starts at exon 3 and the region upstream from that may also contain 
regulatory elements, in addition to a well characterized polymorphism (T-129C).  
 
Polymerase chain reaction (PCR) to amplify the region involved an initial 
denaturation of two minutes at 94
O
C, followed by 25 to 30 cycles of three stages: 
a 15 second denaturation at 94
O
C, a 30 second annealing stage at a primer-
specific amplification, a 30 second elongation at 72
O
C, a final five minute 
elongation stage at 72
O
C and cooling to 4
O
C. PCR conditions were optimised 
using 10 µl reactions, followed by increasing the reaction volume to 50 μl. Each 
reaction contained 2X PCR Master Mix (Fermentas), 1 μM concentration of each 
primer, 10 μl of nuclease-free water and 5 μl (approximately 25 ng) of DNA. A 
control reaction was set up by replacing the DNA with 5 μl of nuclease-free 
water. Successful amplification was determined by electrophoresing the PCR 
product on a 2% agarose gel in the presence of ethidium bromide. 
 
A 774 bp fragment of the 5′ upstream untranslated region of exon 1 was 
amplified using the forward primer MDR15URF and the reverse primer 5UTRR2 
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and an annealing temperature of 53
O
C (Table 2). A 648 bp region surrounding 
exon 2, also known as exon 1b and containing the T-129C locus, was amplified 
using the primers published by Gwee et al. (2003) with forward primer E1Fwd 
and the reverse primer E1Rev and an annealing temperature of 53
O
C (Table 3). 
 
The samples were then purified and concentrated prior to being sent for 
sequencing using Sure Clean from Bioline. The sample was then resuspended in 
distilled water, followed by electrophoresis on a 2% agarose gel to ensure that the 
PCR fragment had not been lost during purification.  
 
The samples were then sent to Inqaba Biotec for sequencing. Two samples were 
amplified in duplicate to initially determine which primer produced a better 
sequence. This primer was then used to sequence the remaining samples. 
Sequences were returned electronically as chromatographs, which were then 
analysed and aligned to the reference sequence (obtained form Ensembl – gene 
number: ENSG00000085563) using the Sequencher
®
 Version 4.5 (Gene Codes 
Corporation, 2005) program. 
 
A number of bioinformatic tools were used to analyse the sequences of the two 
promoter regions. The promoter sequences were entered into each program twice, 
once with the major allele at each SNP and once with the minor allele at each 
SNP, in order to determine if the variation changed the promoter region. 
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PROSCAN Version 1.7 (Prestridge 2000) predicts promoter elements by 
comparing them with eukaryotic polymerase II promoter sequences. The current 
version of the program recognizes close to 70% of primate promoter sequences 
and has a false positive prediction rate of one in 14,000 base pairs (bp). FPROM 
(Solovyev 1997; Solovyev 2001; Solovyev and Shahmuradov 2003) predicts 
potential transcription start sites using functional motifs and sequence 
composition. This program recognizes 80% of TATA promoter sequences with a 
false positive prediction rate of one in 2,000 bp, and recognizes 50% of TATA-
less promoter sequences with a false positive prediction rate of one in 650 bp. 
 
NSITE searches DNA sequences for regulatory motifs using two databases. The 
REGSITE database contains 1,500 functional motifs for genomic or promoter 
sequences. Ghosh is the Animal Transcription Factor Database, containing 8,458 
functional motifs for genomic or promoter sequences. TFSEARCH (Akiyama) 
searches DNA sequences for transcription factor binding sites using the 
TFMATRIX (Heinemeyer 1998) transcription factor binding sites profile 
database.  
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Table 2: Sequences and annealing temperatures for primers used in sequencing 
and genotyping PCR reactions. 
Name Sequence (5′-3′) Size 
(bp) 
Ta (
O
C) 
MDR15URF CTCATTTGAAGGTCTTCCCAGT 22 61 
5UTRR2 TAGGGAGTTATTTCAAAGTTTTTAT 25 55 
E1Fwd GGTGTTAGGAAGCAGAAAG 19 58 
E1Rev ACTATCCACGCCTCAAGA 18 58 
EXON12FC GTCCTGGTAGATCTTGAAGGGC 22 65 
EXON12FT GTCCTGGTAGATCTTGAAGGGT 22 63 
EXON12R ATTTAGCATAAGGACAAGCTATCTC 25 60 
MDR-9 TGCAGGCTATAGGTTCCAGG 20 62 
MDR-10 GTTTGACTCACCTTCCCAG 19 60 
MDR-10a TTTAGTTTGACTCACCTTCCCG 22 61 
ASA3050F TGGTTCTAAGGTTCGGTGA 20 58 
ASA3050RT CCTTTGTATCTAATTTTGCATTA 23 54 
ASA3050RG CCTTTGTATCTAATTTTGCATTC 23 56 
ASA5231FT TCCAAAGGATGATCTGTTTT 20 54 
ASA5231FC TCCAAAGGATGATCTGTTTC 20 56 
ASA5231R TTCCCTCTCCCACAAGAC 18 60 
GT3435F CTCTTGTTTTCAGCTGCTT 19 56 
AE26I26R TCCCAGAAATGTTCCTCTCT 20 58 
AE26I26F TGACAGTTCCTCAAGGCATA 20 58 
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2.4 Genotyping 
 
Seven SNPs in the ABCB1 gene were chosen to be genotyped in all samples in 
order to obtain a large dataset for characterizing the variation in the gene. 
 
The UCSC (http://genome.ucsc.edu/cgibin/hgTracks?position=chr7:8713294887 
229506&hgsid=154228320&knownGene=pack&hgFind.matches=uc011khc.1), 
Ensmbl (http://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000 
085563) and NCBI (http://www.ncbi.nlm.nih.gov/mapview/map_search.cgi?chr= 
hum_chr.inf&query=ABCB1) databases were used to determine the sequences 
surrounding the chosen SNPs and their frequency in other populations. The seven 
polymorphic sites chosen were T-129C in exon 2, C1236T in exon 12, G2677T/A 
in exon 21, G3050T and T5231C in intron 25, C3435T in exon 26 and T80C in 
intron 26, all of which had all been previously associated with variable protein 
expression, or were in high linkage disequilibrium with the C3435T site. The 
relative distances between the seven loci were determined (Figure 3). 
 
Two methods of genotyping were used: PCR (as described in the sequencing 
section) followed by restriction digest or, in the absence of a restriction site, 
allele-specific amplification. Both methods of amplification involved a 10 μl 
PCR reaction of 2X PCR Master Mix, 1 μM concentration of each primer, 2 μl of 
nuclease-free water and 1 μl (approximately 5ng) of DNA. A control reaction 
was set up using 5 μl of nuclease-free water instead of DNA. 
 
  
 
 
 
 
 
 
 
 
 
Figure 3: The relative distances between the seven ABCB1 polymorphisms that were chosen to be genotyped. 
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For the amplifications followed by restriction digest, each sample was amplified 
and one sample was amplified in duplicate to use as an undigested control. 
Amplification was confirmed by electrophoresis of 5 μl on a 2% agarose gel in 
the presence of ethidium bromide. 
 
Restriction digest reactions of 10 μl were set up with 5 U of restriction enzyme, 
1X enzyme-specific buffer, 3.8 μl of nuclease-free water and 5 μl of PCR 
product. Undigested controls were set up replacing the restriction enzyme with 
nuclease-free water. To confirm the function of the enzyme, most restriction 
digetions were designed to include at least one restriction control site, where the 
amplified DNA would be cut, regardless of the genotype. The digestions were 
electrophoresed on agarose gels in the presence of ethidium bromide to determine 
the genotypes. 
 
For allele-specific amplification three primers are required, either one forward 
and two reverse primers, or two forward primers and one reverse primer. For the 
two forward or reverse primers, each primer is specific for one of the two 
possible alleles. The amplification reaction is performed in duplicate, each using 
on of the allele-specific primers. The PCR products are electrophoresed and 
analysed to determine the genotypes. The successful amplification of one reaction 
only indicates a homozygote of the successful allele-specific reaction, whereas 
the successful amplification of both reactions indicates a heterozygote. 
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For all polymorphic sites genotyped, blind replicates of a random selection of 
10% of the samples were performed to confirm the reproducibility of the methods 
and to blindly test the accuracy of genotyping. 
 
To genotype the T-129C polymorphism the same 648 bp region was amplified as 
that used to sequence the 5′ upstream region of exon 3 using the primers E1Fwd 
and E1Rev, an annealing temperature of 53
O
C (Table 2) and the protocol 
designed by Gwee et al. (2003). Amplification was confirmed by electrophoresis 
on a 2% agarose gel in the presence of ethidium bromide. The fragment was 
subjected to restriction digestion at 37
O
C for 2 hours using the enzyme MspA1I, 
which recognises the restriction site CMG/CKG, where M is either A or C and 
where K is either G or T. The restriction site was created in the presence of the  
-129C allele and three control restriction sites were also included (Figure 4a). The 
genotypes were determined from the elctrophoresis of the restriction digest on an 
ethidium bromide containing 4% agarose gel. 
 
The C1236T polymorphism was genotyped using allele-specific amplification of 
a 766 bp fragment using two forward primers (EXON12FC and EXON12FT), 
one common reverse primer (EXON12R) and annealing temperatures of 57
O
C for 
the C allele and 56
O
C for the T allele (Table 2). Ampification was confirmed and 
genotypes allocated by electrophoresis on a 2% agarose gel containing ethidium 
bromide. 
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The G2677T/A polymorphism was genotyped using the protocol from Sigmund 
et al. 2002, which separates the genotyping into G2677A and G2677T. The 
G2677A polymorphism was genotyped by amplification a 220 bp fragment using 
the forward primer, MDR-9, the reverse primer, MDR-10 and an annealing 
temperature of 56
O
C (Table 2). Amplification was confirmed by electrophoresis 
on an ethidium bromide containing 2% agarose gel. The fragment was restricted 
at 65
O
C using the enzyme BsrI, which recognises the restriction site ACTGGN/. 
In the presence of the A allele, the BsrI restriction site was created and the 
fragment was restricted (Figure 4b). Electrophosesis on a 4% agarose gel with 
ethidium bromide was performed to confirm and analyse restriction digestion. 
 
The 224 bp fragment  for genotypinc the G2677T polymorphism was amplified 
using the forward primer MDR-9, the reverse primer MDR-10a and an annealing 
temperature of 57
O
C (Table 2), and confirmed by electrophoresis on a 2% 
agarose gel in the presence of ethidium bromide. The fragment was restricted at 
37
O
C using the enzyme BanI, which recognises the restriction site G/GYRCC, 
where Y is either C or T and R is either A or G. This restriction site is not 
naturally occurring in the ABCB1 exon 21 sequence, but amplification with the 
reverse primer MDR-10a resulted in a mutation being incorporated into the 
amplified fragment to provide a restriction site for BanI in the presence of the G 
allele (Figure 4c). Restrictions were analysed after electrophoresis on a 4% 
agarose gel containing ethidium bromide. Once the two polymorphisms were 
genotyped individually the data was combined to result in the final expected 
genotypes. 
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The IVS 25+G3050T SNP was genotyped by allele-specific amplification of a 
336 bp fragment using one common forward primer (ASA3050F), two reverse 
primers (ASA3050RT and ASA3050RG) at annealing temperatures of 51.1
O
C for 
the T allele and 52
O
C for the G allele (Table 2). Electrophoresis on an ethidium 
bromide containing 2% agarose gel was used to confirm amplification and assign 
genotypes. 
 
Allele-specific amplification of a 293 bp fragment was used to genotypes the IVS 
25+T5231C SNP, using two forward primers (ASA5231FT and ASA5231FC), 
each specific for one allele, one common reverse primer (ASA5231R) at 
annealing temperatures of  47
O
C for the T allele and 48
O
C for the C allele (Table 
2). Samples were allocated genotypes after electrophoresis on a 2% agarose gel 
containing ethidium bromide. 
 
The 477 bp fragment  containing the C3435T SNP was amplified using the 
forward primer GT3435F, the reverse primer AE26I26R and an annealing 
temperature of  47
O
C (Table 2). Electrophoreseis on a 2% agarose gel in the 
presence of ethidium bromide, was used to confirm amplification, for restriction 
at 37
O
C using the enzyme MboI, which recognises the restriction site /GATC. In 
the presence of the C allele, the MboI restriction site was created, the fragment 
was restricted, and control restriction site was also included to verify the function 
of the enzyme (Figure 4d). 
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The IVS 26+T80C SNP wasgenotyped by amplification of a 651 bp fragment 
using the forward primer AE26I26F and the reverse primer AE26I26R at an 
annealing temperature of 53
O
C (Table 2). Amplification was confirmed by 
electrophoresis on an ethidium bromide containing 2% agarose gel. The fragment 
was restricted at 37
O
C using the enzyme Alw26I, which recognises the restriction 
site GTCTC(N)1/. In the presence of the C allele, the Alw26I restriction site was 
created and the fragment was restricted. Two control restriction sites were also 
included to verify the function of the enzyme (Figure 4e). Genotypes were 
assigned after electrophoresis on a 4% agarose gel in the presence of ethidium 
bromide. 
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Figure 4: Restriction patterns for the T-129C, G2677A, G2677T, C3435T and 
IVS 26+T80C polymorphisms based on the size of the amplified fragment, the 
position of the restriction site created by one allele and removed in the presence 
of the other allele, and the presence and position of any control restriction sites. 
The DNA was restricted using the following restriction enzymes: MspA1I, BsrI, 
BanI, MboI and Alw26I, respectively. 
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The genotypic data was entered into a spread-sheet and the bioinformatic tool 
Linkage Disequilibrium Analyser
®
 (LDA) Version 1.0 (Ding et al. 2003) was 
used to test for Hardy-Weinberg. This program is a java-based Graphic User 
Interface and provides an estimation of linkage disequilibrium statistics; it 
performs statistical tests and predicts linkage disequilibrium for autosomal SNPs 
(Ding et al. 2003). The Hardy-Weinberg equilibrium (p
2
 + 2pq + q
2
 = 1) was used 
to determine if the allele and genotype frequencies, for autosomal chromosomes, 
were in equilibrium, meaning that there is no heterozygous excess or selection for 
a specific allele or genotype. This program performs the Chi squared test to test 
whether the data fits the Hardy-Weinberg equilibrium.  
 
This test is a non-parametric, statistical test for two sets of data. It was used to 
test whether the observed and expected genotype frequencies, were similar 
enough for us to say that the observed data does not occur at random. The Chi 
squared equation (χ2 = Σ (o-e)2/e) and the degrees of freedom (df = n-1) for a 
specific threshold or error (5%) are used to determine the p value. If the p value 
falls above the error threshold (p≥0.05) then we can accept the hypothesis that the 
observed data is not significantly different from the expected results. If the p 
value falls below the threshold (p<0.05) then we have to reject the hypothesis that 
the observed and expected data are not significantly different from one another 
(Roshner et al. 1990). 
 
The linkage disequilibrium between a two-locus haplotype can be measured 
using D, expressed as differences between the experimental and expected 
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frequencies in terms of random segregation. D is calculated using the frequency 
of the haplotype formed by the alleles A and B (PAB) and the frequencies of each 
allele undergoing independent assortment (PA and PB), such that D = PAB - PA x 
PB. The numerical value of D is meaningless for comparisons or determining the 
strength of the disequilibrium. Therefore the Lewontin‟s coefficient |D′| (|D′| = 
D/Dmax) and Pearson correlation r
2
 (r
2
 = D/PA x Pa x PB x Pb) are used to quantify 
the degree of linkage disequilibrium.  
 
When |D′| = 1 and r2 = 1, then there is no recombination (complete linkage 
disequilibrium), when |D′| < 1, then there is recombination (linkage 
disequilibrium is destroyed), and when |D′| > 1, then there is no clear 
interpretation. The Lewontin‟s coefficient (|D′|) is strongly dependant on the 
sample size, often leading to conflicting results, since |D′| increases for small 
population sizes. The LDA software was also used to calculate the linkage 
disequilibrium between two alleles. This program was used to calculate the 
Lewontin‟s coefficient |D′| and the Pearson correlation r2 from the genotypic data 
(Lewontin 1964; Hill and Robertson 1968, Shifman et al. 2003; Reich et al. 2001; 
Ardlie et al. 2002; Nsengimana et al. 2004).  
 
The samples with complete genotypic data were used for the haplotype analysis, 
performed using the PHASE version 2.1.1 (Stephens et al. 2001; Stephens and 
Sheet 2005). PHASE was run ten times to determine the reproducibility of the 
output (Stephens et al. 2001; Stephens and Sheet 2005). The expected and 
inferred frequencies were compared for the haplotypes that were most frequent in 
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our data set. The frequencies of the commonly found ABCB1 haplotypes, 
involving the C1236T, G2677T/A and C3435T polymorphisms, were compared 
to haplotype frequencies from other populations.  
 
A reduced median network of common haplotypes was constructed using the 
Network Version 4.510 (Dec. 2008) program designed by Bandelt et al. (1995). 
This program is found on the Fluxus Engineering website and is able to construct 
networks from genotypic or binary data. 
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2.5 cDNA Synthesis using Reverse Transcription of RNA 
 
For all RNA samples the total RNA was reverse transcribed into single-stranded 
cDNA for relative quantification, using the High-Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems) according to the manufacturer‟s 
instructions (Appendix I). The process requires the binding of reverse 
transcriptase enzyme to the RNA molecule. This enzyme facilitates the binding 
of the random primers to the RNA and extension of these primers to form the 
cDNA molecule using dNTPs.  
 
This reaction occurs under optimum conditions, maintained by a buffer. The 
random primers ensure that synthesis of the first cDNA strand proceeds at an 
equal efficiency for all RNA molecules present. An RNase inhibitor is added to 
ensure that the RNA molecules present are not digested by RNase. The PCR 
product was not electrophoresed, since the reaction only synthesised the first 
cDNA strand without amplifying it, and therefore these would only be a few 
copies of the cDNA, not enough to view on an agarose gel. The newly 
synthesised cDNA was used for the quantitative PCR reactions. 
 
 
 
 
 
 
 66 
2.6 Calibrator Normalised Relative Quantification of mRNA 
 
The synthesized cDNA was used for the relative quantification of mRNA, which 
was performed using the TaqMan
®
 Gene Expression Assay (Applied Biosystems) 
according to manufacturer‟s instructions, using TaqMan® MGB probes. These 
probes contain a reported dye (6-FAM), which is linked to the 5′ end of the 
probe, a minor groove binder, which allows the melting temperature of the probe 
to be increased for the design of shorter probes, and a nonfluorescent quencher at 
the 3′ end of the probe. The probes bind at an exon-exon boundary in the ABCB1 
cDNA and the reporter dye is removed during the elongation step in the PCR 
reaction to fluoresce. 
 
For quantification of the levels of mRNA the Calibrator Normalised Relative 
Quantification (ΔΔCt) method was chosen. No standard curve was required as the 
target gene and reference gene (housekeeping gene), were compared to one 
another and no standand curve was needed. We also chose this method for the 
determination of relative amounts of mRNA, as these would be compared with 
the genotypes and haplotypes to determine if these was any association between 
them. The quantification reaction is carried out for each sample for the target 
gene (ABCB1) and a reference gene (human beta-2-microglobulin (B2M) gene). 
The crossing points can then be compared to determine the target/reference ratio.  
 
An additional sample (HIV negative in our case) is chosen to be the calibrator. 
The calibrator is also quantified for both the target and reference genes and is 
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used to normalise the samples in a particular PCR run, as well as between 
different runs. The normalised ratio is then calculated as the target/reference ratio 
for the sample, divided by the target/reference ratio for the calibrator. Each 
sample was amplified in real time with detection for the target and reference 
genes five times to ensure reliable results for analysis. 
 
The target reaction used a TaqMan Gene Expression Assay (hs01067802_ml), 
which consisted of a set of primers that span the exon-exon junctions, preventing 
genomic DNA from amplifying, and specifically amplifying an 84 bp region of 
the ABCB1 cDNA. Of the many available assays for the ABCB1 gene, this one 
spans a region that includes exon 26. The primer sequences, and therefore the 
specific region, were proprietary and could not be obtained. 
 
The endogenous control assay amplified the human beta-2-microglobulin (B2M) 
gene as a reference gene. This gene was chosen as it is expressed uniformly in all 
cells. The popular GAPDH gene was not chosen as a reference gene as this gene 
is not as uniformly expressed as was previously thought (Zhong and Simons 
1999). 
 
The 7500 Software Version 2.0.3 (Applied Biosystems) was used to analyse the 
relative quantification data. The software calculated the Ct values for the target 
and reference genes and calculates the means for the repeats. The Ct value is the 
threshold cycle, which is the cycle number at which the generated fluorescence 
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crosses the threshold line. The average Ct values were determined from the five 
repeats and the standard deviation calculated for each sample average. 
 
The ΔCt value is then calculated by subtracting the Ct (reference) from the Ct 
(target) for the test samples and the calibrator. The ΔΔCt is then calculated by 
subtracting the ΔCt (calibrator sample) from the ΔCt (test sample). The fold 
difference value between the sample and calibrator, or relative quantity (RQ) is 
given by the 2
-ΔΔCt
 value. The ΔΔCt for the calibrator is set to 1, so that all the 
sample fold differences are represented as a fold difference of the calibrator. 
These values were then depicted as a bar chart with standard deviations. 
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2.7 Association Studies 
 
The genotypic and haplotypic data was used for association studies with the 
clinical data was obtained from the Themba Lethu Clinic at Helen Josep Hospital 
and the relative quantificatiug data, to determine if any association could be 
found between variation in the gene and the level of transcription and/ or drug 
response. 
 
The data obtained from the Thamba Lethu Clinic at Helen Josep Hospital 
included the baseline CD4
+
 and viral load counts with dates, the CD4
+
 and viral 
load counts at time point one (as close to six months as possible) with dates, and 
the CD4
+
 and viral load counts at time point two (as close to twelve months as 
possible) with dates. The viral load data was not as complete as the CD4
+
 data, as 
viral load is not always measured at clinical visits. The number of days between 
the baseline measurement and the two time points were established, as visits to 
the clinic were not always strictly at six and twelve months. It was suspected that 
the data would not show distinct time points, but a merger between time points 
one and two. The CD4
+
 cell counts or viral load counts were plotted against the 
days since baseline. 
 
The clinical data and genotypic data files were merged and the data was sorted 
for each SNP by genotype. Line graphs were then constructed to show the 
increase in CD4
+
 or decrease in viral load counts for the genotypes of each SNP 
at the three time points, baseline, time point one and time point two. The SAS 
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9.1.3 software (SAS Institute Inc. Cary NC, USA) was used to perform the 
statistical analyses for association. The analysis of variance (ANOVA) and non-
parametric Kruskal-Wallis tests were chosen based on the papers by Fellay et al. 
(2002) and Nasi et al. (2003), who used these tests for their association studies. 
Fellay et al. (2002) found an association between the 3435TT genotype and low 
P-gp expression and low plasma drug levels. 
 
The mean CD4
+
 counts and viral load counts were claculated for each genotype 
at each polymorphism. The mean CD4
+
 counts and viral load counts were then 
claculated for combinations of SNPs. These were chosen to analyse each of the 
SNPs with the C3435T SNP, and based on linkage disequilibrium data. The 
C1235T-G2677T/A-C3435T haplotype was also chosen as a combination. These 
were used to compare the increse in CD4
+
 count or decrease in viral load for the 
genotypes of the combined SNPs and to compare the combined SNPs with the 
individual ones. 
 
The GLM proceedure was then used to perform an analysis of variance 
(ANOVA) test for association between the individual genotypes and the 
difference in CD4
+
 counts at baseline and time 1, between the individual 
genotypes and the difference in CD4
+
 counts at baseline and time 2, between the 
individual genotypes and the difference in viral load counts at baseline and time 
1, and between the individual genotypes and the difference in viral load counts at 
baseline and time 2. This is a one-way test for determining the difference in 
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means of the dependent variables, by sorting them by levels of the independent 
variable. The proceedure was then repeated using the SNP combinations.  
 
The proportional increase in CD4
+
 count and proportional decrease in viral load 
count was calculated for both time points. The proportional increase or decrease 
was calculated by subtracting the baseline CD4
+
 count or viral load count from 
the CD4
+
 count or viral load count at time point one or two, and dividing this by 
the baseline CD4
+
 count or viral load count. This was done for a better 
comparison the proportional increase or decrease as opposed to the actual CD4
+
 
or viral load counts. The mean proportional increase in CD4
+
 count or decrease in 
viral load count was determined for each genotype of each SNP and for the SNP 
combinations. This data was presented graphically and used to repeat the GLM 
procedure in SAS, to determine any association between the proportional increase 
or decrease and the different genotypes. 
 
The mean relative quantification (RQ) values corresponding to each genotypes of 
each SNP were calucluated and presented graphically for comparison. The mean 
RQ values for the SNP combinations were also calculated and presented 
graphically for comparison betwwen genotypes and between the single and 
combined SNPs. A t-test was performed to determine any association between 
the RQ values and genotypes. This allows the testing of significant difference 
between the sample means and the hypothesised value. In our analysis the 
hypothesised value was one, as the RQ values were being compared to the 
calibrator value. 
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A non-parametric version of the ANOVA test, the Kruskal-Wallis test, was 
performed in SAS to test for association between the individual genotypes and 
RQ values. This test only allowed for two variables to be compared and therefore 
the GLM ANOVA test was performed in SAS to determine and association 
between the different genotypes of the SNPs or SNP combinations, the RQ values 
and the mean proportional difference in CD4
+
 counts at time point 1 and time 
point 2, and between the different genotypes of the SNPs or SNP combinations, 
the RQ values and the mean proportional difference in viral load counts at time 
point 1 and time point 2. 
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CHAPTER 3: RESULTS 
 
3.1 Samples 
 
For the 42 general population samples, the average DNA concentration was 51.8 
ng/μl, for the 105 HIV positive samples from the Infectious Disease Clinic at 
Johannesburg Hospital, the average concentration was 46.5 ng/μl, the 64 HIV Net 
samples were at a concentration of 20 ng/μl and the 207 blood samples that were 
collected from the Themba Lethu HIV Clinic at the Helen Joseph Clinic in 2006 
and 2009 had an average concentration of 9.4 ng/μl. The genomic DNA was 
diluted to working solutions with concentrations of approximately 5 ng/μl. From 
the samples collected in 2009, all individuals whose DNA and RNA were 
successfully extracted were on the regiment IA antiretrovirals, which all have 
efaviranze as one of the combination drugs. 
 
 
 
3.2 DNA and RNA Extraction from Whole Blood 
 
DNA was successfully extracted from all samples and run on 0.8% agarose gels 
to verify the presence and purity of DNA (Figure 5). Of the 104 samples for 
which the RNA extraction was performed, only 28 samples were successful 
(Figure 6).  
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Figure 5: Agarose gel (0.8%) showing integrity of DNA extraction from whole 
blood of HIV positive patients. The agarose gel was also used to determine if 
there was RNA contamination, which was not present in any of the above 
samples. Lane 1 containes a 1 kb molecular weight marker as a reference, and 
lanes 2 to 15 contain DNA samples from different patients. The concentrations 
are different due to the different amounts of white blood cells obtained from the 
patients. 
 
500 bp 
750 bp 
1000 bp 
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Figure 6: Integrity of RNA extraction from whole blood HIV positive samples 
visualized on a 2% agarose gel. Lane 1 contains a 1 kb molecular weight marker 
and lanes 2 to 8 contain successful RNA extractions from different patients. All 
the extracted RNA samples had genomic DNA contamination, but for the 
samples that extracted successfully bands for both the 18S and 28S rRNA were 
visible. An attempt was made to remove the contaminated DNA, but this resulted 
in the loss of all nucleic material in the sample. The removal of DNA 
contamination was not necessary though, due to the nature of the primers used for 
quantitative PCR. 
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3.3 Sequencing 
 
The PCR product of the amplification of the region upstream of exon 1 was 
electrophoresed to confirm sucessful amplification of the 774 bp fragment 
(Figure 7).  
                                               1     2     3     4     5     6 
 
 
Figure 7: Confirmation of the region upstream of exon 1 by electrophoresis on a 
2% agarose gel in the presence of ethidium bromide by a single band. The size of 
the 774 bp fragment was confirmed by a standand graph (R
2
 value = 0.9995). 
 
The PCR products for the amplification of the exon 2 region were 
electrophoresed to determine if amplification was successful. Successful 
amplification was seen as a single band 648 bp in size (Figure 8).  
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Figure 8: Electrophosesis on an ethidium bromide containing 2% agarose gel to 
confirm amplification of the fragment containing exon 2 (1b). The 648 bp 
fragment was confirmed by a standard curve (R
2
 = 0.9992). 
 
The 5′ untranslated region upstream from exon 1 was sequenced in 32 samples, 
revealing 4 polymorphisms: at positions A-137C, T-196C, G-223A and G-298A, 
numbered from exon 1 (Table 3). For the T-196C SNP both homozygotes and the 
heterozygote were found, for the A-137C, G-223A and G-298A polymorphisms 
only one homozygote and the heterozygote were detected. 
 
The upstream region from exon 2 (also known as 1b) was sequenced, as 
transcription only begins with exon 3 and one polymorphic site in particular has 
been analysed in this region (T-129C). Twenty samples were sequenced and 5 
polymorphic sites were observed: A-60T and A-41G in intron 1, T108G, G153A 
and T-129C in exon 2 (Table 3). All the samples showed homozygozity for only 
250 bp 
500 bp 
750 bp 
1000 bp 
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one allele. For the T-129C site the minor allele frequency is the highest, whereas 
in the other polymorphic sites only one out of the 20 samples had the variation, 
all of which were in the form of heterozygotes.  
 
Table 3: Summary of the analysis from the sequence data from the two upstream 
regions of the ABCB1 (87133175 – 87342611) 
 
Upstream 
Region 
No. SNP Status rs Number Minor Allele 
Frequency 
Exon 1 
(87343026 – 
87342553) 
32 A-137C Novel - 0.01 (C) 
T-196C Known rs4148727 0.13 (C) 
G-233A Novel - 0.04 (A) 
G-298A Novel - 0.06 (A) 
Exon 2 
(87230607 – 
87229959) 
20 A-60T Known rs113117 0.05 (T) 
A-41G Known rs11126 0.05 (T) 
T108G Novel - 0.05 (G) 
G153A Novel - 0.05 (A) 
T202C Known rs3213619 0.2 (C) 
 
All novel SNPs were submitted to GenBank and have the following accession 
numbers: A-137C (JF775576), G-223A (JF775577), G-298A (JF775578), T108G 
(JF775579) and G153A (JF775580). 
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The sequence data was used for bioinformatic analysis of both upstream regions. 
The sequence with the major alleles for all SNPs found and the sequence with the 
minor alleles for all SNPs found were used for the analysis and compared (Tables 
4 & 5). 
 
Table 4: Comparison of outputs from various bioinformatic promoter analysis 
programs for the sequence upstream of exon 1 with major or minor alleles 
 
Program Sequence with major alleles Sequence with minor alleles 
PROSCAN No promoter region predicted No promoter region predicted 
FPROM No promoter/ enhancers 
predicted 
No promoter/ enhancers 
predicted 
NSITE 6 human motifs found 
(REGSITE) 
11 human motifs found 
(Ghosh) 
6 human motifs found 
(REGSITE) 
12 human motifs found 
(Ghosh) 
TFSEARCH 87 vertebrate TF binding 
sites found 
89 vertebrate TF binding 
sites found 
 
The PROSCAN, FPROM and PROMOTER 2.0 programs did not predict any 
promoter elements in the region upstream of exon 1. The additional motif found 
by NSITE using the Ghosh database in the sequence containing the minor alleles 
was a Lymphokine CS motif (GGGGTTTCAC) in the presence of the -137G 
allele. 
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Two additional transcription factor binding sites were found by TFSEARCH in 
the sequence containing the minor alleles. The -223T allele creates a CdxA 
binding site (TATTTTT) which is absent in the presence of the -223C allele. The 
-137G allele creates an AML-1a binding site (TGGGGT) which is absent in the 
presence of the -137T allele. 
 
Table 5: Comparison of outputs from various bioinformatic promoter analysis 
programs for the sequence upstream of exon 2 with major or minor alleles 
 
Program Sequence with major alleles Sequence with minor alleles 
PROSCAN No promoter region predicted No promoter region predicted 
FPROM No promoter/ enhancers 
predicted 
No promoter/ enhancers 
predicted 
NSITE 8 human motifs found 
(REGSITE) 
14 human motifs found 
(Ghosh) 
8 human motifs found 
(REGSITE) 
14 human motifs found 
(Ghosh) 
TFSEARCH 48 vertebrate TF binding 
sites found 
48 vertebrate TF binding 
sites found 
 
The PROSCAN and FPROM programs did not predict any promoter elements in 
the region upstream of exon 3. The NSITE program, using the Ghosh database, 
found 12 motifs identical in both sequences. The sequence with the major alleles 
also has the alpha-1-proteinase inhibitor (GGGGCGTGGGCTGAG) and ABCB1 
(GGGCTGAGCA) motifs which are both due to the presence of the 153G allele 
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and are not found in the sequence with the minor allele as the 153G allele is 
replaced with the 153A allele. 
 
The sequence with the minor alleles also has a P-LAP (CTCATTCGAGCAGCG) 
motif due to the presence of the minor 202C (-129C) allele and, which is absent 
in the sequence with the major 202T (-129T) allele. The minor 108G allele 
creates the TCR-Vbeta-8.1 (TCTGTGGGGA) motif, which is not present in the 
sequence with the major 108T allele. 
 
TFSEARCH found the same number of transcription factor binding sites in both 
sequences, but two polymorphisms altered the sequence from one transcription 
factor binding site to another. The major -60A creates a binding site for CdxA 
(CATAA), but the minor -60T allele changes this to a binding site for Nkx-2 
(TACTTAA). The major 180T allele is situated in the binding site for AML-1a 
(TGTGGT), but the minor 180G allele changes this to a binding site for MZF 1 
(TGTGGGGA). 
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3.4 Genotyping 
 
The products of the PCR and restriction digestion reactions were eletrophoresed 
on agarose gels containing ethidium bromide to confirm amplification and 
restriction digestion, and to ensure correct fragment sizes after amplification and 
digetion (Figures 9 to 16). The sizes of the fragments were estimated by 
comparing the bands with the bands of known size of the molecular weight 
marker and confirmed using standard curves. The reliability of the standard curve 
is determined by the R
2
 value, with a value close to 1 being the most reliable. The 
agarose gels following allele-specific amplification or restriction digestion were 
used to assign genotypes to the samples. 
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Figure 9: Restriction digestion of the 648 bp PCR fragments amplified for the 
exon 2 T-129C region, by MspA1I confirmed by the presence of bands after 
electrophoresis on a 4% agarose gel. Lane 1 contains the 1 kb molecular weight 
marker, lanes 2 to14 contains restricted DNA for different samples and lane 15 
contains the undigested control sample. The PCR amplified fragment sizes and 
restricted fragment sizes were confirmed using standard curves (R
2
 = 0.9995 and 
R
2
 = 0.988 respectively). 
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Figure 10: Allele-specific amplification of the exon 12 C1236T fragment 
confirmed by the presence of bands after electrophoresis on a 2% agarose gel in 
the presence of ethidium bromide. Lane 1 contains a 1 kb molecular weight 
marker, lanes 2 to 6 contain samples amplied for the T allele, lane 7 contains the 
control sample for T allele amplification, lanes 8 to 12 contain samples amplified 
for the C allele and lane 13 contains the control sample for C allele amplification. 
The sample sizes were confirmed by a standatd curve (R
2
 = 0.9898). 
 
 
 
 
 
 
 
 
 
1000 bp 
750 bp 
500 bp 
250 bp 
 85 
                                  1     2      3    4      5    6     7     8      9   10   11   12   13   14    
                              
 
Figure 11: Restriction digest of samples amplified for the 220 bp exon 21 
G2677A fragment by BsrI, confirmed by the presence of bands after 
electrophoresis on a 4% agarose gel in the presence of ethidium bromide. Lane 1 
contains a low range molecular weight marker, lanes 2 to 12 contain restriction 
digestions for different samples and lane 13 contains the undigested control 
sample. Amplified and digested fragment sizes were confirmed by standard 
curves (R
2 
= 0.9811 and R
2 
= 0.9996, respectively). 
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Figure 12: Electrophoresis on an ethidium bromide containing 4% agarose gel to 
confirm restriction digestion by BanI of samples amplified for the 224 bp exon 21 
G2677T fragment. Lane 1 contains a 100 bp molecular weight marker, lanes 2 to 
14 contain restriction digestions of different samples, and lane 15 contains an 
undigested control sample. Amplification and restriction fragment sizes were 
confirmed using standard curves (R
2
 = 0.9996 and R
2
 = 0.9904, respectively). 
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Figure 13: Allele-specific amplification of the 336 bp IVS 25+G3050T fragment, 
confirmed by the presence of a single band after electrophoresis on a 2% agarose 
gel in the presence o ethidium bromide. Lane 1 contains a 1 kb molecular weight 
marker, lanes 2 to 7 contain PCR products of different samples amplified for the 
T allele, lane 8 contains the control for the T allele reaction, lanes 9 to 14 contain 
the PCR products of different samples amplified for the G allele, and lane 15 
contains the G allele control. The fragment sizes were confirmed using a standard 
curve (R
2 
= 0.9996). 
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Figure 14: Confirmation of allele-specific amplification of the 293 bp IVS 
25+T5231C fragment by electrophoresis on an ethidium bromide containing 2% 
agarose gel. Lane 1 contains a 1 kb molecular weight marker, lanes 2 to 7 contain 
PCR products of different samples amplified for the T allele, lane 8 contains the 
T allele control reaction, lanes 9 to 14 contain the PCR products of different 
samples amplified for the C allele, and lane 15 contains the C allele control 
reaction. Fragment sizes were confirmed using a standard curve (R
2 
= 0.9968). 
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Figure 15: Restriction digest of samples amplified for the 447 bp exon 26 
C3435T fragment by MboI, confirmed by the presence of bands after 
electrophoresis on a 2% agarose gel containing ethidium bromide. Lane 1 
contains a 50 bp molecular weight marker, lanes 2 to 12 contain the restriction 
digestions of different samples, and lane 13 contains the undigested control 
sample. The amplification and restriction digestion fragment sizes were 
confirmed using standard curves (R
2 
= 0.9998 and R
2
 = 0.9965, respectively).  
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Figure 16: Restriction digest of samples amplified for the 652 bp IVS 26+T80C 
region by Alw26I, confirmed by the presence of bands after electrophoresis on a 
2% agarose gel in the presence of ethidium bromide. Lane 1 contains a 50 bp 
molecular weight marker, lanes 2 to 14 contain restriction digestions of different 
samples, and lane 15 contains the undigested control sample. Amplification and 
restriction digestion fragment sizes were confirmes using standard curves  
(R
2 
= 0.9996 and R
2
 = 0.9865, respectively). 
 
 
250 bp 
50 bp 
100 bp 
150 bp 
200 bp 
300 bp 
400 bp 
 91 
Between 354 and 385 samples were successfully genotyped for the seven 
polymorphic sites (Table 6). The allele frequencies were calculated from the 
genotypes and compared to allele frequencies from European populations 
(Soranzo et al. 2004 and Takane et al. 2004). The genotypic data and the 
following analysis thereof were done by first separating the general population 
samples from those of the HIV positive samples, and then for all samples 
together. The data for the general population was not significantly different from 
that of the HIV positive samples, which was why the data was chosen to be 
presented for all samples together. 
 
The minor allele frequencies are lower than those found in the studies on 
Europeans, except for the 5231 locus, which shows a very similar minor allele 
frequency, and the T-129C locus which has a higher minor allele frequency. The 
frequencies for the 1236T and 3435T alleles are much lower in the southern 
African population compared to the European population (Soranzo et al. 2004). 
The χ2 test was performed using the genotyping frequencies and showed no 
significant deviation from Hardy-Weinberg equilibrium, except for the 2677 
locus (Table 6).  
 
The χ2 test was not the most appropriate test for the G2677T/A polymorphism, as 
more than two alleles are possible, resulting in some genotype groups with small 
numbers, for which the χ2 test is can not accurately calculate the χ2 and P values 
for. The Fisher‟s exact test is able to handle SNPs with more than two possible 
alleles and produced a P value was 0.195 (> 0.05), when the 2677T and 2677A 
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allele frequencies were combined, indicating no significant deviation from the 
expectations of Hardy Weinberg equilibrium. 
 
All the linkage disequilibrium values for the Lewontin‟s coefficients and Pearson 
correlations were found to be less than 1 and greater than zero, except for the 
Pearson correlation between G2677T/A and C3435T, and between G2677T/A 
and  IVS 26+T80C, which were found to be zero (Table 7). The three highest |D′| 
values were found between C1236T and IVS 26+T80C (0.75), C1236T and 
C3435 (0.74), and between T-129C and C3435T (0.69). The lowest |D′| value 
was between G2677T/A and IVS 26+T80C (0.01). The three highest r
2
 values 
were seen between C3435T and IVS 26+T80C (0.39), C3435T and IVS 25+3050 
(0.13) and between IVS 26+T80C and IVS 25+3050 (0.12). The lowest r
2
 value 
was seen between T-129C and C1236T (0.0001).  
 
The linkage disequilibrium values obtained from our data were compared to the 
values obtained by Soranzo et al. 2004 for Europeans. The r
2
 values for our data 
are much lower than those for Europeans (Table 8). The |D′| values for all but the 
1236-3435 and 1236-IVS 26+80 pairs were greater in the data from Soranzo et al. 
(2004). The linkage disequilibrium with the T-129C site could not be compared 
as this site was not included in the Soranzo et al. (2004) study. 
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Table 6: Genotypic data with test for Hardy-Weinberg equilibrium. 
Locus dbSNP rs# Chr. 
Position 
No DF Observed Genotype 
Number 
Hardy-
Weinberg 
Equilibrium 
χ2          P 
MAF  
(My data) 
MAF 
(Europeans
a
) 
T-129C  
(UTR) 
rs3213619 87230193 354 2 253 
 (TT) 
95 
 (TC) 
6 
 (CC) 
0.87 >0.05 0.15 (C) 0.02 (C) 
C1236T  
(Exon 12) 
rs1128503 87179601 385 2  33 
(CC) 
 163 
(CT) 
 189 
(TT) 
0.13 >0.05 0.30 (C) 0.47 (T) 
G2677T/A  
(Exon 21) 
rs2032582 87160618 376 3  216 
(GG) 
 136 
(GA) 
 12 
(GT) 
9.44 <0.05 0.23 (A/T) 0.47 (A/T) 
 0 
(AA) 
 1 
(TT) 
 11 
(AT) 
IVS 25+G3050T 
(Intron 25) 
rs1002204 87141497 374 2  281 
(GG) 
 81 
(GT) 
 12 
(TT) 
2.62 >0.05 0.14 (T) 0.40 (T) 
IVS 25+ T5231C 
(Intron 25) 
rs4437575 87139316 385 2  104 
(TT) 
 188 
(TC) 
 93 
(CC) 
0.91 >0.05 0.49 (C) 0.42 (C) 
C3435T  
(Exon 26) 
rs1045642 87138645 375 2  290 
(CC) 
 79 
(CT) 
 6 
(TT) 
0.02 >0.05 0.12 (T) 0.42 (C) 
IVS 26+T80C 
(Intron 26) 
rs2235048 87138511 362 2  285 
(TT) 
 74 
(TC) 
 3 
(CC) 
1.47 >0.05 0.11 (C) 0.43 (C) 
a
 Soranzo et al. 2004
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Table 7: Linkage disequilibrium estimates for all polymorphic pairs. 
 
 T-129C C1236T G2677T/A IVS 25+G3050T IVS 25+T5231C C3435T IVS 26+T80C 
T-129C - 0.0001 0.0005 0.005 0.0008 0.01 0.004 
C1236T 0.04 - 0.007 0.02 0.0002 0.03 0.03 
G2677T/A 0.09 0.23 - 0.002 0.004 0.00 0.00 
IVS 25+ 
G3050T 
0.43 0.55 0.06 - 0.03 0.13 0.12 
IVS 25+ 
T5231C 
0.07 0.02 0.11 0.46 - 0.01 0.03 
C3435T 0.69 0.74 0.06 0.38 0.30 - 0.39 
IVS 26+T80C 0.40 0.75 0.01 0.39 0.51 0.65 - 
Lewontin’s coefficient (|D′|) 
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Table 8: Linkage disequilibrium estimates for all polymorphic pairs from the data from Soranzo et al. (2004). 
 
 C1236T G2677T/A IVS 25+G3050T IVS 25+T5231C C3435T IVS 26+T80C 
C1236T - 0.213 0.587 0.349 0.190 0.199 
G2677T/A 0.565 - 0.350 0.786 0.901 1.000 
IVS 25+G3050T 0.896 0.623 - 0.563 0.399 0.327 
IVS 25+T5231C 0.788 0.934 0.877 - 0.795 0.800 
C3435T 0.566 1.000 0.728 0.892 - 0.909 
IVS 26+T80C 0.583 1.000 0.651 0.944 1.000 - 
                                              Lewontin’s coefficient (|D′|) 
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A total of 383 samples were used for the haplotype analysis. This number was 
obtained by including only samples, for which at least four of the seven 
polymorphisms had been successfully genotyped. Based on the alleles present in 
the data set, there were 152 possible haplotypes, and 56 of these were detected in 
the data set. PHASE was able to resolve 38% of the haplotype pairs, with 62% 
remaining ambiguous. 
 
The 10 most common haplotypes in our data set with the frequencies inferred by 
PHASE, using the haplotype population frequencies, and the expected 
frequencies obtained from our allele frequencies, where haplotype 1 is the most 
common (Table 9). All ten runs resulted in the exact same data. The most 
common haplotyes with respect to positions -129, +1236, +2677, IVS 25+3050, 
IVS 25+5231, +3435, IVS 26+80 were TTGGTCT (15,5%), TTGGCCT (12,7%), 
TCGGCCT (12,5%), TCGGTCT (10,6%), TTAGCCT (10,1%), CTGGCCT 
(4,8%), TTGTTCT (3,4%), CTGGTCT (3,4%), TTGTCTC (2,9%), TTAGTCT 
(2,0%). 
 
The most commonly reported ABCB1 haplotype is 1236-2677-3435. The 
frequencies of various phases of this haplotype were compared in a number of 
populations, where the South African data represents our data, compared to data 
for the Benin population in West Africa (Allabi et al 2005), African Americans 
(AfAm) (Kim et al. 2001; Tang et al. 2002), Caucasians (Cauc) (Kim et al. 2001; 
Tang et al. 2002) and Chinese (Tang et al. 2002) (Figure 17). 
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Table 9: Comparison of the inferred and expected frequencies of the 10 most common haplotypes. 
         Locus 
Haplotype 
-129 
T/C 
1236 
C/T 
2677 
G/T/A 
IVS 25+ 3050 
G/T 
IVS 25+ 5231 
T/C 
3435 
C/T 
IVS 26+ 80 
T/C 
Frequency 
Inferred    Expected 
1 T T G G T C T 0.155 0.160 
2 T T G G C C T 0.127 0.172 
3 T C G G C C T 0.125 0.088 
4 T C G G T C T 0.106 0.081 
5 T T A G C C T 0.101 0.054 
6 C T G G C C T 0.048 0.035 
7 T T G T T C T 0.034 0.030 
8 C T G G T C T 0.034 0.030 
9 T T G T C T C 0.029 0.016 
10 T T A G T C T 0.020 0.037 
 
 98 
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
CGC TTT CGT TGT TGC CTC CTT TTC CAC TAC TAT CAT
Haplotypes 1236-2677-3435
F
re
q
u
en
cy
South Africa Benin (Allibi et al. 2005) African Americans (Tang et al. 2002)
African Americans (Kim et al. 2001) Caucasians (Tang et al. 2002) Caucasians (Kim et al. 2001)
Chinese (Tang et al. 2002)
 
Figure 17: Bar chart for the comparison of the common ABCB1 1236-2677-3435 haplotype in various populations.  
The CGC phase has been found to be most common in West African and African 
American populations, whereas the TTT phase has been found to be most 
common in non-African populations. The CGC occurs at a much lower frequency 
than would be expected, as we would expect the data to be similar to that of other 
African-originating populations. The TTT phase is at a very low frequency, as 
expected since those three alleles are at a low frequency in our data set but at a 
high frequency in European populations, but is also lower than the frequencies 
observed in West Africans and African Americans. For the CGT, CTC, CTT, 
TTC, CAC, and TAT phases, the frequencies are very low. For the TGT phase 
the frequency is approximately the same as for the other populations of African 
origin. The TGC phase occurs at a frequency of 43% and is the most common 
phase of this haplotype in our data. It is at a much higher frequency then in any 
other population, with the next highest frequency being about 18% in the 
Chinese. The TAC phase occurs at a frequency of about 15% and the CAT phase 
was not found at all in our data. 
 
Two reduced median networks were constructed for the 10 most common 
haplotypes (Table 9). The first was generated using the haplotypes of all seven 
polymorphisms (Figure 18). The second was generated using the haplotypes of 
the six closest polymorphisms and excluding the T-129C polymorphisms to 
determine any difference in the pattern of the network seen by removing the most 
distant variant (Figure 19). The ancestral haplotypes, based on those present in 
other primate sequences (www.ensemble.org), (TCGGTCT and CGGTCT) are 
coloured green. 
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There is only one base difference between most of the ten haplotypes. With all 
seven SNPs there is one haplotype that is three base changes different from two 
other haplotypes. The most common change is at the 5231 locus and the least 
common changes are at the 3435 and 80 loci. With only six SNPs there are three 
haplotypes that are two base changes different from other SNPs. The most 
common changes are at the 3050 and 5231 loci. 
 
 
Figure 18: Reduced Median Network for the 10 most common haplotypes for all 
seven polymorphisms. 
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 Figure 19: Reduced Median Network for the 10 most common haplotypes for the 
six closest polymorphisms. 
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3.5 Calibrator Normalised Relative Quantification of mRNA 
 
The Ct values for each repeat were used to determine the mean Ct values, the ΔCt,   
ΔΔCt and RQ (2
-ΔΔCt
) values with standard deviations for each sample (Appendix 
III). The positive and negative deviation was calculated for the RQ values for 
each sample, as well as for the mean RQ (Table 10). 
 
The sample RQ values are compared to the calibrator, whose value is set to one. 
Sample 1180 has the highest RQ value, but also has the greatest standard 
deviation, whereas sample 1179 has the lowest RQ value and a very small 
standard deviation (Figure 20). 
 
The t-test of the RQ values produced a t value of -4.09 and a p value of 0.0004, 
which is less than the significance threshold of α = 0.05, indicating significant 
differences between the RQ values. 
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Table 10: RQ Values with standard deviation for 28 samples and mean RQ. 
Sample RQ (2
-ΔΔC 
) Positive deviation Negative deviation 
1036 0.23 0.23 0.12 
1038 0.61 0.23 0.16 
1057 0.85 0.51 0.33 
1066 0.48 0.39 0.22 
1081 0.42 0.13 0.1 
1087 0.24 0.17 0.11 
1106 0.35 0.25 0.14 
1129 0.3 0.26 0.14 
1137 0.96 0.71 0.41 
1141 0.25 0.17 0.1 
1150 0.37 0.42 0.2 
1153 0.68 0.45 0.27 
1156 1.05 0.33 0.25 
1158 0.86 0.21 0.17 
1169 0.85 0.18 0.15 
1173 0.78 0.39 0.26 
1174 0.59 0.4 0.23 
1175 0.41 0.67 0.25 
1176 0.71 0.16 0.12 
1178 1.42 0.35 0.28 
1179 0.2 0.08 0.06 
1180 1.66 1.84 0.88 
1182 0.86 0.22 0.17 
1184 0.86 0.15 0.12 
1185 1.16 0.25 0.21 
1191 0.98 1.04 0.5 
Mean  0.70 0.39 0.28 
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Figure 20: Bar chart of RQ values and standard deviations for 28 samples, generated from five repeats of relative quantification using 
cDNA. RQ values are compared to the Calibrator, set to a value of one, ordered from the highest to lowest RQ value. 
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3.6 Association Studies    
 
The CD4
+
 counts for the 151 available samples were compared at three time 
points, baseline, time point one, and time point two, given in days since baseline. 
In terms of the clinic‟s database, time point one is supposed to be as close to six 
months as possible (+/- 180 days) after baseline readings, and time point two is 
supposed to be as close to twelve months as possible (+/- 360 days) after baseline 
readings. The viral load data was not as complete as the CD4
+
 data and was only 
available for 46 samples. We plotted the CD4
+
 counts against the number of days 
since baseline and instead of producing clear time intervals, the time points were 
located over a range of days, often overlapping between time points one and two 
(Figure 21). 
 
The same comparison was made using the viral load data. Due to the high values 
at baseline compared to time points one and two, the log values of viral load were 
used. The viral load counts were plotted against the number of days since 
baseline and a wide range of time points was observed (Figure 22). 
 
Inconsistency in patient visits to the clinic produces an overlap in the data points 
for the two time points, instead of distinct groupings around 180 days and 360 
days. This is pattern is observed for both the CD4
+
 count and viral load data. 
There are fewer data points for the viral load data, as this is not measured as 
consistently at clinic visists as CD4
+
 counts. 
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Figure 21: CD4
+
 counts for three time points: baseline (time zero), time point one 
(as close to six months or 180 days as possible) and time point two (as close to 
twelve months or 360 days as possible). Instead of distinct clusters around 180 
and 360 days, the data points form a large cluster over a large time interval and 
there is an overlap between data points from time points one and two. 
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Figure 22: Log viral load counts for three time points: baseline (time zero), time 
point one (as close to six months or 180 days as possible) and time point two (as 
close to twelve months or 360 days as possible). Instead of distinct clusters 
around 180 and 360 days, the data points form a large cluster over a large time 
interval and overlap between the time points one and two. 
 
The mean CD4
+
 counts were grouped into the different genotypes of each 
polymorphism to compare the increase in mean CD4
+
 count between each 
genotype at the three time points: baseline, time point one and time point two 
(Figure 23). The haplotypes that were resolved by PHASE were too few to 
include in the association studies, so the mean CD4
+
 counts were also grouped 
into combinations of SNPs, based on linkage disequilibrium data, and the 
increase compared between each genotype combination. The combination of 
C1236T, G2677T/A and C3435T was also used to analyse the mean CD4
+
 count 
data for each genotype combination (Figure 24). 
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Figure 23: Increase in mean CD4
+
 counts for the genotypes of each of the T-
129C, C1236T, G2677T/A, IVS 25+G3050T, IVS 25+T5231C, C3435T and IVS 
26+T80C polymorphisms at baseline, time point one and time point 2. 
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Figure 24: Increase in mean CD4
+
 counts for the genotype combinations of each 
of the SNP combinations T-129C/C3435T, C1236T/C3435T, 
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G2677T/A/C3435T, IVS 25+G3050T/C3435T, IVS 25+T5231C/C3435T, IVS 
26+T80C/C3435T, C1236T/ IVS 26+T80C, C1236T/G2677T/A and  
C1236T/G2677T/A./C3435T polymorphisms at baseline, time point one and time 
point 2. 
 
An ANOVA test was performed to test for association between the genotypes and 
the difference in CD4
+
 counts at baseline and time 1, and the difference in viral 
load counts at baseline and time 2, for the individual SNPs (Table 11). All P 
values were above the level of significance α = 0.05, indicating that there was no 
association for any of the SNPs at either time point. 
 
The ANOVA test between the genotypes and the difference in CD4
+
 counts at 
baseline and time 1, the difference in CD4
+
 counts at baseline and time 2 for the 
SNP combinations showed no association for any of the SNP combinations. The 
order of SNPs for sorting the data was altered to determine any change in the 
results, but there was still no detectable association using SNP combinations. The 
ANOVA test was run a second time, this time without the outlying samples. All P 
values were above 0.05, indicating no significant difference and no association. 
 
A student‟s t test showed that there was a table-wide significant difference 
between the p values from the ANOVA test (p = 0.017). 
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Table 11: Results of the ANOVA test for testing the association between the 
SNPs and mean CD4
+
 count differences at the first and second time points.  
 
Variables DF F value p value 
T-129C; Time1 15 1.26 0.3061 
T-129C; Time2 8 0.54 0.8071 
C1236T; Time1 21 0.95 0.5491 
C1236T; Time2 12 0.94 0.5429 
G2677T/A; Time1 21 0.71 0.7663 
G2677T/A; Time2 12 1.04 0.4757 
IVS 25+G3050T; Time1 7 0.56 0.7796 
IVS 25+G3050T; Time2 5 0.44 0.8235 
IVS 25+T5231C; Time1 22 1.17 0.3849 
IVS 25+T5231C; Time2 16 0.58 0.8317 
C3435T; Time1 10 0.72 0.6970 
C3435T; Time2 8 1.69 0.1761 
IVS 26+T80C; Time1 11 1.68 0.1345 
IVS 26+T80C; Time2 8 1.36 0.2855 
 
The mean viral load counts were grouped into the different genotypes of each 
polymorphism to compare the decrease in mean viral load count between each 
genotype (Figure 25) and each genotype combination for the SNP combinations 
(Figure 26) at the three time points: baseline, time point one and time point two.  
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Figure 25: Decrease in mean viral load counts for the genotypes of each of the T-
129C, C1236T, G2677T/A, IVS 25+G3050T, IVS 25+T5231C, C3435T and IVS 
26+T80C polymorphisms at baseline, time point one and time point 2. 
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Figure 26: Decrease in mean viral load counts for the genotype combinations of 
each of the SNP combinations T-129C/C3435T, C1236T/C3435T, 
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G2677T/A/C3435T, IVS 25+G3050T/C3435T, IVS 25+T5231C/C3435T, IVS 
26+T80C/C3435T, C1236T/ IVS 26+T80C, C1236T/G2677T/A and 
C1236T/G2677T/A./C3435T polymorphisms at baseline, time point one and time 
point 2. 
 
An ANOVA test was performed to test for association between the genotypes and 
the difference in viral load counts at baseline and time 1, and the difference in 
viral load counts at baseline and time 2, for the individual SNPs (Table 12). 
There was no data available for the second time points for the T-129C, C1236T, 
IVS 25+G3050T and IVS 26+T80C SNPs, so association cound not be tested for. 
For the IVS 25+T5231C and C3435T SNPs the P values were above the 
significance level of α = 0.05 but the P value for the G2677T/A polymorphism 
was 0.0121, indicating a significant difference in the mean viral load count at the 
second time point. Only two genotypes were found to correlate with the viral load 
data, 2677GG and 2677GA, the two most common genotypes for this 
polymorphism. At the fist time point the viral load counts at each genotype have 
decreased, but at the second time point the viral load counts for the 2677GA 
genotype have increased significantly compared to the 2677GG genotype. 
 
The ANOVA test between the genotypes and the difference in viral load counts at 
baseline and time 1, the difference in viral load counts at baseline and time 2 for 
the SNP combinations showed no association for any of the SNP combinations. 
The order of SNPs for sorting the data was altered to determine any change in the 
results, but there was no detectable association using SNP combinations. The 
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ANOVA test was run a second time, this time without the outlying samples. All P 
values were above 0.05 for the first time point, indicating no significant 
difference and no association, and the P value for the G2677T/A polymorphism 
at time point two remained 0.0121. 
 
A student‟s t test showed that there was a table-wide significant difference 
between the p values from the ANOVA test for the mean viral load counts  
(p < 0.0001). 
 
Table 12: Results of the ANOVA test for testing the association between the 
SNPs and mean viral load count differences at the first and second time points. 
 
Variables DF F value p value 
T-129C; Time1 3 0.33 0.8009 
C1236T; Time1 3 0.24 0.8683 
G2677T/A; Time1 2 0.64 0.5507 
G2677T/A; Time2 2 81.70 0.0121 
IVS 25+G3050T; Time1 2 0.32 0.7375 
IVS 25+T5231C; Time1 3 0.05 0.9835 
IVS 25+T5231C; Time2 2 0.09 0.9238 
C3435T; Time1 1 0.51 0.4908 
C3435T; Time2 1 0.02 0.8956 
IVS 26+T80C; Time1 2 0.04 0.9633 
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The mean proportional increase in CD4
+
 counts for each genotype (Figure 27) 
and genotype combination (Figure 28) and mean proportional decrease in viral 
load counts each genotype (Figure 29) and genotype combination (Figure 30) 
were calculated at each of the two time point.  
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Figure 27: Mean proportional increase in CD4
+
 count for each genotype at each 
polymorphism at time points one and two. 
 
Mean Proportional Increase in CD4+ counts for T-129C 
Genotypes 
-8.00
-4.00
0.00
4.00
8.00
12.00
16.00
TT TC CC
Genotypes
M
e
an
 P
ro
p
o
rt
io
n
al
 In
cr
e
as
e
 in
 C
D
4
+
 
co
u
n
ts
Time Point 1 Time Point 2
Mean Proportional Increase in CD4
+
 counts for C1236T 
Genotypes 
-8.00
-4.00
0.00
4.00
8.00
12.00
16.00
20.00
24.00
CC CT TT
Genotypes
M
e
a
n
 P
ro
p
o
rt
io
n
a
l 
In
cr
e
a
se
 i
n
 
C
D
4
+
 c
o
u
n
ts
Time Point 1 Time Point 2
Mean Proportional Increase in CD4
+
 counts for G2677T/A 
Genotypes 
-8.00
-4.00
0.00
4.00
8.00
12.00
16.00
GG GA GT TA
Genotypes
M
e
a
n
 P
ro
p
o
rt
io
n
a
l 
In
cr
e
a
se
 i
n
 
C
D
4
+
 c
o
u
n
ts
Time Point 1 Time Point 2
Mean Proportional Increase in CD4
+
 counts for IVS 
25+G3050T Genotypes 
-8.00
-4.00
0.00
4.00
8.00
12.00
16.00
GG GT TT
GenotypesM
e
a
n
 P
ro
p
o
rt
io
n
a
l 
In
cr
e
a
se
 
in
 C
D
4
+
 c
o
u
n
ts
Time Point 1 Time Point 2
Mean Proportional Increase in CD4+ counts for IVS 
25+T5231C Genotypes 
-6.00
-3.00
0.00
3.00
6.00
9.00
12.00
15.00
TT TC CC
GenotypesM
e
a
n
 P
ro
p
o
rt
io
n
a
l 
In
cr
e
a
se
 
in
 C
D
4
+
 c
o
u
n
ts
Time point 1 Time Point 2
Mean Proportional Increase in CD4
+
 counts for C3435T 
Genotypes 
-5.00
0.00
5.00
10.00
15.00
CC CT TT
Genotypes
M
e
a
n
 P
ro
p
o
rt
io
n
a
l 
In
cr
e
a
se
 
in
 C
D
4
+
 c
o
u
n
ts
Time Point 1 Time Point 2
Mean Proportional Increase in CD4+ counts for IVS 
26+T80C Genotypes 
-7.00
0.00
7.00
14.00
21.00
TT TC CC
GenotypesM
e
a
n
 P
ro
p
o
rt
io
n
a
l 
In
cr
e
a
se
 
in
 C
D
4
+
 c
o
u
n
ts
Time Point 1 Time Point 2
 118 
 
Figure 28: Mean proportional increase in CD4
+
 count for each genotype 
combination for each polymorphism combination at time points one and two. 
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The Kruskal-Wallis test was performed to determine any association between 
genotypes and the mean proportional increase in CD4
+
 count at each time point, 
instead of the mean values for the absolute difference between baseline and the 
two time points. All SNPs had P values above the significance value of α = 0.05 
(Table 13). There was no association detected for any of the SNP combinations 
using the proportional increases. A student‟s t test showed that there was a table-
wide significant difference between the p values from the Kruskal-Wallis test  
(P < 0.0001). The Kruskal-Wallis test was repeated, omitting the outlying 
samples, yielding no change in the P values. 
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Table 13: Results of the Kruskal-Wallis test for association between the SNPs 
and the mean proportional increase in CD4
+
 count at the first and second time 
points. 
 
Variables DF χ2  value p value 
T-129C; Time1 2 0.9196 0.6314 
T-129C; Time2 2 1.2446 0.5367 
C1236T; Time1 2 0.8569 0.6515 
C1236T; Time2 2 0.9072 0.6353 
G2677T/A; Time1 3 3.2451 0.3554 
G2677T/A; Time2 3 4.8799 0.1808 
IVS 25+G3050T; Time1 2 0.6067 0.7383 
IVS 25+G3050T; Time2 2 0.9763 0.6138 
IVS 25+T5231C; Time1 2 4.3688 0.1125 
IVS 25+T5231C; Time2 2 0.6974 0.7056 
C3435T; Time1 2 3.3430 0.1880 
C3435T; Time2 2 2.5727 0.2763 
IVS 26+T80C; Time1 2 0.9239 0.6301 
IVS 26+T80C; Time2 2 0.8400 0.6571 
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Figure 29: Mean proportional decrease in viral load count for each genotype at 
each polymorphism at time points one and two. 
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Figure 30: Mean proportional decrease in viral load count for each genotype 
combination for each polymorphism combination at time points one and two. 
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The was performed to determine any association between genotypes and the 
mean proportional increase in CD4
+
 count at each time point, instead of the mean 
values for the absolute difference between baseline and the two time points 
(Table 14). The P values for all SNPs at both time points were above the 
significance value of α = 0.05, except for the T-129C SNP, where the P value for 
the first time point was determined to be 0.0029. There was no association 
detected for any of the SNP combinations using the proportional increases. A 
student‟s t test showed that there was a table-wide significant difference between 
the p values from the Kruskal-Wallis test (P = 0.0053).The Kruskal-Wallis test 
was repeated without the outlying samples and no significant difference in P 
values was found. 
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Table 14: Results of the Kruskal-Wallis test for association between the SNPs 
and the mean proportional increase in viral load count at the first and second time 
points. 
 
Variables DF χ2  value p value 
T-129C; Time1 2 11.6661 0.0029 
T-129C; Time2 1 1.4913 0.2220 
C1236T; Time1 2 0.7068 0.7023 
C1236T; Time2 2 0.7726 0.6796 
G2677T/A; Time1 2 2.7645 0.2510 
G2677T/A; Time2 1 0.7271 0.3938 
IVS 25+G3050T; Time1 2 0.3899 0.8229 
IVS 25+G3050T; Time2 2 0.6465 0.7238 
IVS 25+T5231C; Time1 2 1.3316 0.5139 
IVS 25+T5231C; Time2 2 0.6395 0.7263 
C3435T; Time1 1 0.0631 0.8017 
C3435T; Time2 1 0.5136 0.4736 
IVS 26+T80C; Time1 1 0.0353 0.8509 
IVS 26+T80C; Time2 1 2.5296 0.1117 
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The mean RQ values corresponding to each genotype of each SNP were 
calculuated (Figure 31) as were the mean RQ values for the SNP combinations 
(Figure 32). As there were only 28 samples that could be used for cDNA 
synthesis and subsequent quantitative PCR, not all genotypes were present in 
those samples. 
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Figure 31: Mean RQ values for each genotype of each of the seven 
polymorphisms. 
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Figure 32: Mean RQ values for each genotype combination for each of the 
polymorphism combinations. 
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The Kruskal-Wallis test showed that there are no significant associations for the 
test for association between the SNPs T-129C, C1236T, G2677T/A and IVS 
25+T5231C and the mean RQ values, the P values were above the significance 
value of 0.05. The Kruskal-Wallis test for association between the two genotypes 
found for each of the SNPs IVS 25+G3050T, C3435T and IVS 26+T80C and the 
mean RQ values, the P values were below the significance value of α = 0.05 
(Table 15). A student‟s t test showed that there was a table-wide significant 
difference between the p values from the Kruskal-Wallis test (p < 0.0001). 
 
Table 15: Results of the Kruskal-Wallis test for association between the 
genotypes of the SNPs and the RQ values. 
 
Variables DF χ2 p-value 
T-129C; RQ 1 0.0067 0.9349 
C1236T; RQ 2 1.7911 0.4084 
G2677T/A; RQ 1 0.1666 0.6831 
IVS 25+G3050T; RQ 1 5.0570 0.0245 
IVS 25+T5231C; RQ 2 0.8377 0.6578 
C3435T; RQ 1 3.8890 0.0486 
IVS 26+T80C; RQ 1 5.1077 0.0238 
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CHAPTER 4: DISCUSSION 
 
Regulation of ABCB1 expression 
 
Sequencing of both upstream non-coding reagions resulted in the detecteion of 
novel variation and only some of the known Polymorphisms. This was in line 
with our expectations of finding different variation in the South African 
population, based on previous studies in other African populations (Tishkoff et al. 
2009). Of the two well studied SNPs in the upstream region of ABCB1, only the  
T-129C polymorphism was confirmed by sequencing, and later genotyped, 
whereas the A-41G was not detected as polymorphic in this population. The 
presence of known polymorphisms at different allele frequencies, novel variation 
and lack of variation at some known polymorphic sites confirms that African 
populations have a different level of variation compared to other populations. The 
undetected polymorphisms may be present in the population, but at very low 
frequencies. 
 
From the bioinformatic analysis it is clear that variation in the upstream region 
can alter the structure of the regulatory elements. In the region upstream of exon 
1 no promoter was predicted and a transcriptional start site is not likely in either 
the forward or reverse strands. The -137G allele creates a Lymphokine CS motif 
and an AML-1a transcription factor binding site, while the -223C allele creates a 
CdxA transcription factor binding site.  
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In the region upstream of exon 3 there was marginal promoter prediction from 
PROMOTER 2.0, which could be due to CpG islands in the upstream region. 
There is a strong correlation between CpG islands and vertebrate promoters 
(Ohler et al. 2000; Ohler et al 2001) and the region upstream of exon 3 may 
contain a number of CpG islands (Takane et al 2004). PROSCAN or FPROM did 
not predict any promoters. The 153A allele disrupts both an alpha-1-protinase 
inhibitor motif and an ABCB1 motif. The 180G allele creates a P-LAP motif and 
changes an AML-1a transcription factor binding site to a MZF binding site. The -
60T allele changes a CdxA transcription factor binding site to an Nkx-2 binding 
site.  
 
The impact of the novel variation and changes to the motifs and transcription 
factor binding sites in the upstream regions is not clear, as not much is known 
about the regulation of expression of the gene, but the variation may result in 
altered transcription. The transcription factors regulating ABCB1 transcription 
have not been well studied and the removal or addition of binding sites could 
impact gene regulation. It is unclear at this point what impact the creation of new 
transcription factor binding sites is likely to have on the regulation of the gene 
and it is also unclear if any of the detected promoter elements influence the 
regulation of transcription of this gene and what impact the changes these SNPs 
may have on that regulation. Functional studies need to be conducted to 
determine the effects, if any, of the detected variation in the two upstream regions 
of the ABCB1 gene. 
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Genetic Structure in the ABCB1 gene 
 
The results have shown very different allele frequencies in the southern African 
Bantu speaking population for all but the IVS 25+T5231C polymorphism (T 
allele = 0.51), which has a similar allele frequency to that seen in Caucasians (T 
allele = 0.58) (Soranzo et al. 2004). The increased frequency of the 1236T allele 
(0.70 in this study, compared to 0.47 in the European study by Soranzo et al. 
2004) is obvious in the analysis of the C1236T-G2677T/A-C3435T haplotype, 
where the TGC phase has the highest frequency, as opposed to the CGC phase, 
which was expected to have the highest frequency based on allele frequencies in 
the West African and African American populations (Kim et al. 2001; Tang et al. 
2002; Allabi et al. 2005). The impact of the higher 1236T allele is not known, as 
all other populations show the 1236C allele to be at the highest frequency of the 
two. 
 
The 3435C allele was found at a much higher frequency (0.88) than in the 
European populations (0.42, Soranzo et al. 2004), which we expected due to 
studies done previously on West Africans (Allabi et al. 2005). The high 
frequency of the 3435 C allele in Africans has been suggested to be due to 
selection for this allele, as the high prevalence of this allele corresponds with a 
lower prevalence in inflammatory bowel disorders (Schaeffeler et al. 2001). No 
alternative suggestions or explanations have been found. 
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Studies by Hoffmeyer et al. (2000) and Kimchi-Sarfaty et al. (2007) showed that 
the silent 3435 C to T polymorphism could change the folding and function of the 
P-glycoprotein. Silent single nucleotide changes could have an effect on the 
mRNA structure, the protein folding pathway, protein translation and protein 
structure (Fung and Gottesman 2009). 
 
The differences in allele frequancies are the direct cause of the very low levels of 
linkage disequilibrium and different haplotypes and haplotype frequencies for 
this gene in the southern African population. Soranzo et al. 2004 published 
linkage disequilibrium values for a number of SNPs paired with C3435T for a 
European population. When we compared these with the linkage disequilibrium 
values for the same pairs in our population, the |D′| and r2 values were much 
lower. The lower values in the South African population were expected, but the 
very high values in the European population studied by Soranzo et al. (2004) 
could be due to a small sample size (48 different samples), or the generally higher 
levels of linkage disequilibrium seen in other populations compared to African 
populations. Notably there is virtually no linkage disequilibrium between the 
G2677T/A locus and either of the C3435T or IVS 25+T80C loci, which have 
almost complete linkage in the Caucasian population depicted in the data by 
Soranzo et al. (2004).  
 
It is difficult to compare LD between sites or between populations, as there is no 
perfect measure of LD (Lewontin, 1988) and factors such as population size and 
allele frequency may influence LD measures (Hendrick, 1987; Lewontin, 1988). 
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Our values for |D′| and r2 are, however, greatly different and much lower than the 
values reported for other populations. It is not only population processes that 
have led to the low LD in this gene.  
 
Variation in linkage disequilibrium estimates and allele frequencies in different 
populations is due to a number of factors, including genetic drift, migration, 
population structure and natural selection (Ardlie et al. 2002; Shifman et al. 
2003). A number of linkage disequilibrium measures are available, but caution 
needs to be exercised when using a particular measure. Two commonly used 
measures are |D′| and r2 (Δ2). The range of |D′| is independent of the allele 
frequencies, whereas all other measures are dependant on allele frequency 
(Hendrick 1987; Lewontin 1988).  
 
The measure |D′| is preferred as it can take a maximum value of 1 if there is 
complete linkage disequilibrium, meaning that any one allele is only seen with 
one allele at the other locus and only three of the possible four haplotypes are 
seen (Teare et al. 2002), however, |D′| is dependant on sample size, with a small 
increase in low |D′| values seen as the sample size decreases (Teare et al. 2002).  
 
The measure r
2
 can reach a maximum of 1 when there is complete linkage 
disequilibrium, and when the two polymorphisms have equal allele frequencies. 
Intermediate values of r
2
 can be interpreted, but only when the two 
polymorphisms have equal allele frequencies (Devlin and Risch 1995; Jorde 
2000; Reich et al. 2001; Ardlie et al. 2002; Teare et al. 2002). There is no perfect 
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measure of linkage disequilibrium, making it difficult to compare populations 
with different allele frequencies (Lewontin 1988). African populations show 
especially distinct differences as opposed to non-African populations, as they 
have more haplotypes and lower levels of linkage disequilibrium between alleles 
(Jorde et al. 1998; Reich et al. 2001, Tishkoff and Williams 2002; Tishkoff et al. 
2009).  
 
The genotypic data was used for the haplotype analysis in PHASE. There is much 
debate as to the reproducibility of the output obtained from any haplotype 
analysis software. There are many haplotype inferral programs available that 
often result in multiple solutions and haplotype inferrals are not usually assessed 
(Orzack et al. 2003). The programs are usually written using data from 
populations with European ancestry and may not be relevant to non-European 
populations. The programs are also unable to deal with heterozygotes and low 
levels of linkage disequilibrium (Orzack et al. 2003). For this reason, ten runs 
were performed independently of each other, and analysed to determine the 
reproducibility of the outputs. All ten outputs showed the exact same data, 
validating the output for further analysis. The majority of the ten most common 
haplotyes contained the 1236T, 2677G, 3435C and IVS 26+80T alleles, which is 
not surpising, as these four alleles occur at very high frequencies (0.7, 0.77, 0.88 
and 0.89, respectively). 
 
The most common phases seen in the ten most common haplotypes are the IVS 
25+G3050T-C3435T-IVS 26+T80C GCT phase, which occurs in eight out of the 
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top ten, and the G2677T/A-C3435T- IVS 26+T80C GCT phase, which is present 
in seven of the top ten. None of the other loci show any pattern of occurrence 
with other loci.  
 
The most commonly studied haplotype in ABCB1 is C1236T-G2677T/A-
C3435T. The frequencies of the different phases were compared with those found 
in a number of other studies. The TTT phase is expected to be the most common 
in non-African populations and the lowest in African populations, which was 
confirmed by our data, whereas the CGC phase is expected to be the most 
common in African populations and the least common in non-African 
populations. From our data is seen that the CGC phase frequency is much lower 
than in any other populations. Based on studies on West African and African 
American populations, we expected the frequency of this phase to higher than the 
observed frequency. The reason for the lower frequency of this phase and the 
higher frequency of the TGC phase is the difference in the C1236T allele 
frequencies, where the 1236T allele is found at a much higher frequency then any 
other population.  
 
The TGC phase occurs at the highest frequency in our data (~ 43%) with all other 
populations showing a very low frequency of this phase with the next highest 
frequency seen in Chinese (~ 18%). For the remaining phases of this haplotype 
the frequencies are very low or they were not found, except for the TAC phase, 
which occurred at a frequency of ~ 15%. 
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In their 2009 review article, Fung & Gottesman looked at the possible 
accumulative effects that the C1236T, G2677T/A and C3435T polymorphisms 
might have on protein function. The 3435C>T mutation  may  affect the co-
translational folding of certain proximal amino acids, which are located in the 
second ATP-binding domain and may reduce the ATP-binding affinity of P-
glycoprotein (Loo and Clarke 1995; Muller et al. 1996; Szakacs et al. 2000; 
Urbatsch et al. 2000; Urbatsch et al. 2001). The affect of the 1236C>T mutation 
is also synonymous and does not affect mRNA stability, protein expression or 
protein function (Wang et al. 2005). It is possible that this site may also affect the 
co-translational folding of certain proximal amino acids, which are located in the 
first ABC domain, and may affect ATP-binding and ATP hydrolysis (Fung and 
Gottesman 2009; Kim et al. 2006; Sakurai et al. 2007).  
 
The 2677G>T mutation has been suggested to impact drug transport and possibly 
affect drug-induced ATPase activity (Fung and Gottesman 2009; Sakurai et al. 
2007). Fung & Gottesman (2009) suggest that all three mutations may each only 
have a small impact on the function of the protein, but added together as a 
haplotype, they may be additive and have a greater effect on protein folding and 
subsequent function. The TTT haplotype is found at a frequency of about 40% in 
Caucasians, but is very rare in our population. This again suggests that any 
advancement made in this field of ABCB1 research is irrelevant to the southern 
African and probably other African populations as well. 
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The high frequency of the TGC phase is very likely to be due to selection for this 
phase in our population, but this finding is not unexpected, as the allele 
frequencies at these three loci are quite different from other populations. The 
1236C allele in our population is present at a frequency of 30%, compared to the 
53% in Caucasians. This results in this allele being the minor allele in our 
population but the major allele in Caucasians. Similarly the 3435T allele is 
present at a frequency of 12% in our population, but at 58% in Caucasian. This 
allele is also the minor allele in our population but the major allele in Caucasians.  
 
The frequency of the 2677G allele is higher in our population (77%) than in the 
Caucasian population (53%). These differences in the allele frequencies manifest 
themselves in the differences in the frequencies of the phases seen for this 
haplotype in our analysis. The levels of linkage disequilibrium between these 
three sites are also different from the Caucasian population. Between C1236T 
and G2677T/A and between G2677T/A and C3435T our data shows lower levels 
of linkage compared to the Caucasian population. Between the C1236T and 
C3435T loci the linkage seen in our data is slightly higher than that in the 
Caucasian population. These differences may also impact the frequency of the 
phases of this haplotype. 
 
Laboratory-based or manual haplotyping is expensive and time consuming. The 
PHASE program is regarded to be quite accurate, based on studies using non-
African populations but computationally expensive. Haplotypes determined by 
manual haplotyping are more informative than genotypes, but inferred haplotypes 
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are often less informative than genotypes due to possible uncertainties in phasing 
calculations and ambiguous haplotypes (Malhi 2002; Orzack et al 2003; Balding 
2006). Our haplotype analysis produced a large number of ambiguous haplotypes 
for the samples, as a result of the reduced levels of linkage disequilibrium seen in 
the population. Manual haplotyping would be an effective method of determining 
the accuracy of the haplotype predictions in the Southern African population and 
to resolve the ambiguous haplotypes. The size of the ABCB1 gene would be 
problematic, but the closer SNPs could be used as a starting point. 
 
The most common haplotypes could have originated only through either multiple 
mutations or recombination between SNPs. Other groups have investigated 
haplotype evolution (Kroetz et al. 2003; Tang et al. 2004) and found some 
evidence for recombination using other SNPs and other populations.  
 
Reduced median networks were constructed for all seven sites, as well as the six 
sites without the T-129C site, as this one is the most distant. For both networks it 
is clear that multiple mutations and recombination events have occurred to 
produce the haplotype phases found in the southern African population. The 
squares in the network that are produced between different phases show that 
multiple single mutations or recombination events took place. In the network 
constructed for the seven polymorphisms the multiple single mutations 
recombinations involve the T-129C, C1236T, G2677T/A, IVS 25+G3050T and 
IVS 25+T5231C sites, with the IVS 25+T5231C polymorphisms being the most 
common variant. Only one phase involved single mutations or recombinations of 
 139 
both the C3435T and IVS 26+T80C polymorphisms. This is also indicative of the 
two sites being linked.  
 
In the network constructed for only six polymorphisms there are multiple single 
mutations and recombination events involving all six sites. The IVS 25+G3050T 
and IVS 25+T5231C polymorphisms are the most common variants between the 
phases. Both networks confirm that a single functional site could not be 
extrapolated based on haplotypes, due to the presence of multiple mutations and 
recombination events in the southern African population.  
 
The genotyping data from the general population samples and those from HIV 
positive individuals showed no significant deviation, so no comparison was 
possible for the genotype or haplotype data. The samples were limited to the 
number of volunteers who were prepared to donate blood, and although the study 
was limited to Bantu-speaking South Africans living in the Johannesburg area, 
the study could be expanded to a much larger sample size and the individual 
language groups studied. 
 
Quantitative mRNA levels 
 
The use of real-time for quantifying mRNA expression levels has not always 
been reproducible from one paper to another (Bustin 2002), as there are a number 
of aspects that can change from one experiment to another. Human error can 
cause variability due to the handling of reagents and the amounts of reagents 
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added for the reaction. The endogenous controls have been re-examined and a 
number of genes used as endogenous controls (e.g. GAPDH) for their consistant 
expression, have been found to be expressed differently in some tissues or under 
certain conditions. Suggestions have been made to include the use of multiple 
endogenous controls for the samples to be normalized against to ensure more 
consistant and believable results (Schmittgen and Zakrajsek 2000; Bustin 2002). 
 
The quantitative PCR data showed variable relative amounts of mRNA compared 
to the endogenous control. The t-test showed no significant difference in the RQ 
values in the 28 samples, meaning that no particular sample (or samples) have 
significantly higher or lower RQ values than the other samples. Quantitative PCR 
is used to quantify the steady state mRNA levels only, and is not an indication of 
the levels of transcription or mRNA stability. The RNA levels cannot be used to 
infer information about the protein production in the cell (Bustin 2002). 
 
Association studies 
 
Population association studies are useful for identifying patterns of differences in 
polymorphisms in individuals with different disease states. These patterns could 
then be used to identify alleles that enhance the risk of the disease or alleles that 
could be effective in the prevention or treatment of the disease. The problem with 
this lies in the fact that the human genome is so large, that any patterns that are 
suggestive of causal polymorphisms may have arisen by chance and not be 
selected for (Balding 2006; Manolio et al. 2009). 
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Fellay et al. (2002) found association between the 3435 TT genotype and higher 
CD4
+
 cell counts and a better decrease in viral load after six months, but Nasi et 
al. (2003) found that the C3435T polymorphism did not have any effect on 
response to therapy over the same time intervale. A meta-anlysis by Leschziner et 
al. (2006) found no association between ABCB1 polymorphisms and drug 
reactions.  
 
The association studies aimed to establish if there was significant association 
between any particular genotype of any polymorphism (or combination of 
polymorphisms) and either relative mRNA values, an increase in CD4
+
 or a 
decrease in viral load. For the mean viral load data, there was a significant 
difference (P = 0.0121) between the mean viral load counts at time point two for 
the G2677T/A polymorphism, with the 2677GA genotype (52 samples) showing 
a significantly higher mean viral load count than the 2677GG genotype (57 
samples). An association was found between the decrease in viral load and the T-
129C SNP, as the P value was below 0.05 for the first time point and the TT 
genotype showed the lowest mean proportional decrease and was also present at 
the highest frequency of the T-129C genotypes. 
 
For the IVS 25+G3050T, C3435T and IVS 26+T80C SNPs the P values were 
below 0.05 for the association between the SNP genotypes and the mean RQ 
values. For all three SNPs the heterozygotes showed higher mean RQ values than 
the major allele homozygote, and the minor allele homozygote was not present in 
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any of the samples. This could indicate that the major allele homozygotes are 
associated with lower relative mRNA levels than the heterozygotes.  
 
The number of samples (twenty-eight) and number of genotypes present for the 
study (none of the minor alleles homozygotes were found for comparison), 
suggests that not enough data was available for any association seen to be truely 
meaningful. A larger number of samples with a better representation of genotypes 
would be required to determine any true association. Table-wide significance 
studies showed significant differences between the P values in all the association 
studies tables.  
 
The lack of association could also be due to the fact that the patients, that were 
sampled, were primarily on efavirenz-based ART. Efavirenz is not a substrate of 
P-gp and the association between the ART responses of individuals taking 
efavirenz has not been substancially proven. The lack of association found in the 
study could be an indication that there may, in fact, be no association between the 
effect of efavirenz and variation in ABCB1 or P-gp.  
 
Another fact to consider is the adherence issue of patients receiving ART in 
South Africa. Many patients are embarrassed to admit to their families and 
friends that they are HIV-positive and will not take their medication when they 
fear detection by family and friends, resulting in irregular adherence to their 
treatment. Patients do not always stick to their regular appointment dates and a 
high deviation exists between the dates of their clinical appointment and the date 
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they visit the clinic. After their visit to determine the baseline viral load and 
CD4
+
 counts, patients are meant to have these measured every 6 months, but due 
to the irregularity of the visit to the clinic, the first two measurements are named 
time point one and two. This could also have affected the data for association 
studies. A larger sample size, with individuals that adhere to their medication and 
visit the clinic regularly, and protein expression data would be required to gain a 
better understanding of the effects of the polymorphisms and any possible 
associations. 
 
Genome wide association studies (GWAS) have become popular for identifying 
common causal variants throughout the human genome and inferring other 
genotypes based on the identified variables. This requires more than 30,000 well-
chosen polymorphisms, relies on the presence of high levels of linkage 
disequilibrium within the genome, for the inferral of genetic structure for 
association studies (Balding 2006, Manolio et al. 2009; Need and Goldstein 
2009). GWAS aim to provide data that can be used to predict disease risk, to 
improve the understanding of complex diseases for improved treatment and to 
identify subclasses of similar diseases (Gibson and Goldstein 2007).GWAS 
would allow screening of the entire genome to identify the major variation 
conferring susceptibility on common diseases, for clinical advances and 
personalizing medicine,  and is thought to be the potential scientific realization of 
major projects such as the Human Genome and the HapMap projects (Gibson and 
Goldstein 2007; McCarthy et al. 2008).  
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GWAS have their limitations, as the majority of studies have been conducted in 
populations of European ancestry, with no focus on populations of recent African 
ancestry, where genetic variation is the greatest and the linkage disequilibrium is 
the lowest (McCarthy et al. 2008; Manolio et al. 2009).  
 
Our analysis of the genetic structure of the ABCB1 gene has shown that the 
variation in the southern African population is different from that of other 
populations, even compared to the West African populations, and has very low 
levels of linkage disequilibrium, making the use of genome wide association 
studies impractical or impossible if this is a valid indication of the entire genome. 
Genetic studies will have to rely on the manual characterisation of the genes by 
genotyping or possibly by whole-genome sequencing and cannot rely on data 
obtained from studies on other populations. For GWAS to be successful there 
needs to be extensive research into the genetic structure and linkage 
disequilibrium of different populations, as well as admixed populations, where 
different patterns of linkage disequilibrium are also ovserved (McCarthy et al. 
2008; Price et al. 2008). Due to the small sample size available for the association 
studies, it seems unlikely that any of the polymorphisms are associated with 
immune response at either of the time points and no association was found 
between the C3435T polymorphism and immune response, indicating that the 
ABCB1 gene may not be involved in immune response with antiretroviral 
therapy. More functional studies are required to add to the information that will 
determine the molecular mechanism behind the variation in the ABCB1 gene. 
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There is some debate as to the usefulness of studying a particular population, as 
„race‟ and „ethnicity‟ are largely social categories and generalisations made about 
a particular population could be detrimental (Mountain & Risch 2004; Sankar et 
al. 2007). It has been suggested that research be conducted with a focus on 
individuals rather than on a population (Feldman et al. 2003). The genomes of 
two southern African individuals (Archbishop Desmond Tutu, a South African 
Bantu-speaker, and !Gubi, a Namibian hunter-gatherer) have recently been 
sequences, confirming the different genetic structure and highlighting the need to 
study more southern African genomes (Ledford 2010). We feel that there is 
enough evidence to show that the southern African population is sufficiently 
genetically different from other populations to warrant studying their variation 
(Jorde et al. 1998; Reich et al. 2001; Tishkoff and Williams 2002). Due to this 
difference in variation, also shown in our data, functional studies performed in 
other populations may not be applicable to this population. Also, due to the high 
prevalence of HIV and poverty in sub-Saharan Africa studies based on the 
individual may not be financially or logistically possible. 
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CHAPTER 5: CONCLUSIONS 
 
This study is the beginning of the characterization of the variation in the ABCB1 
in the black South African population, which has again proven that variation in 
this population is different compared to non-African populations, and that there is 
an importance in characterizing variation in this population. A number of novel 
SNPs and some known SNPS were detected in the two regulatory regions 
sequences cause changes to regulatory elements found in those regions, but the 
impact of these changes are not known as the promoter regions are well 
characterized and the regulation of the ABCB1 gene is not well understood.  
 
The genotypic data obtained from seven SNPs, thought to of some level of 
functional importantance, clearly shows that variation in the ABCB1 gene in the 
southern African population is very different from that in other populations, even 
when compared to other African populations. This affects the allele frequencies, 
the linkage disequilibrium values as well as the frequency of haplotypes and the 
frequency of haplotype phases. The genetic structural differences warrent larger 
studies to characterize variation in this population, to improve to healthcare in 
this population. 
 
There may be some association between the -129 TT genotype and a lower mean 
proportional decrease in viral load counts at a later stage of treatment, and there 
may be an association between each of the major allele homozygotes of the IVS 
25+G3050T, C3435T and IVS 26+T80C polymorphisms with lower mean 
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relative mRNA levels. Due to the small sample size it is unlikely that any true 
association exists between the ABCB1 polymorphisms and immune response, but 
a larger sample size would be required to confirm this. Work is still needed to 
determine the means by which variation in this gene results in the altered 
presence or function of P-glycoprotein. 
 
The differences in the genetic structure of the gene indicate that genome wide 
association studies and other functional studies based on other populations will 
not be applicable to the southern African population. This population is so 
genetically diverse, that genome wide association studies may not be possible in 
this population, due to both the amount of variation between this population and 
other populations, as well as within the population itself. As a result, population-
based determination of an individual‟s likely response to certain drugs, as well as 
population- or individual-based drug therapy may not be logistically or 
financially possible in the southern African population.  
 
No significant association was found between variation in ABCB1 and immune 
recovery with HIV therapy. A larger study, both in sample number and in the 
number of sites characterized, combined with functional studies is needed to 
better understand the mechanisms by which variation in ABCB1 affect the 
functional variation of P-glycoprotein, as well as the mechanisms by which 
variation in P-glycoprotein are associated with an individuals response to 
antiretroviral therapy. 
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APPENDIX I 
 
A) Instructions for DNA extraction using the QIAGEN QIAmp DNA Blood 
Mini Kit 
 
The leukocyte-rich buffy coat was obtained by centrifuging the blood vial at 
2,500 x g for 10 minutes at room temperature. The buffy coat was removed and 
200 μl added to 20 μl of protinase K, 4 μl of RNase A and 200 μl of lysis buffer 
(buffer AL) in a 1,5 ml microcentrifuge tube. An incubation at 56
O
C for 10 
minutes ensured protein and RNA digestion, as well as cell lysis. The sample was 
briefly centrifuged for 15 sec at 8,000 x g at room temperature to remove the 
drops of liquid from the lid. Ethanol (200 μl) was added to precipitate the DNA, 
the sample was mixing by pulse-vortexing for 15 seconds and then briefly 
centrifugation at 8,000 x g at room temperature.  
 
The sample was added to the spin column in a 2 ml collection tube, centrifuged 
for 1 min at 8,000 x g at room temperature in order to bind the DNA to the 
column. The column was placed in a new collection tube and the filtrate, with the 
enzymes, buffer and ethanol, discarded. The DNA was washed by adding 500 μl 
of wash buffer (buffer AW1), followed by centrifugation at 8,000 x g for 1 min at 
room temperature. The column was placed in a new collection tube and the 
filtrate discarded. The DNA was washed a second time by adding 500 μl of wash 
buffer (buffer AW2), followed by centrifugation at full speed (13,400) at room 
temperature for 3 min to wash the DNA and a further 1 minute to eliminate buffer 
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carry over. The column was placed in a clean 1,5 ml microcentrifuge tube, the 
filtrate was discarded, 200 μl of storage buffer (buffer AE) added, followed by 
incubation at room temperature for 1 min. The sample was centrifuged at 8,000 x 
g for 1 min at room temperature to elute the DNA. The sample was stored in 
buffer AE instead of water to avoid hydrolysis.  
 
B) TRIzol LS extraction of whole RNA  
 
The blood vials were centrifuged at 2,500 x g for 10 minutes at room temperature 
to obtain the leukocyte-rich buffy coat. The buffy coat was removed and 250 μl 
was added to 750 μl of TRIzol LS. The samples are vortexed to homogenise the 
solutions and 200 μl of chloroform was added. The tubes were shaken vigorously 
by hand for 15 sec and incubated at room temperature for 2-15 min. 
Centrifugation at 12,000 x g at 4
O
C for 15 min separated the solution into two 
phases. The top layer contained the RNA and was transferred to a clean tube. The 
lower layer contained DNA, proteins and other cell material and was discarded. 
 
To resuspend the RNA 500 μl of isopropyl alcohol was added to the tube, which 
was then incubated at room temperature for 10 min and centrifuged at 12,000 x g 
at 4
O
C for 10 min, to produce a pellet of RNA. The supernatant was removed and 
the RNA pellet was washed once with 1 ml of 75 % ethanol. The ethanol was 
added to the pellet, the tube was briefly vortexed and then centrifuged at 7,500 x 
g at 4
O
C for 5 min. To resuspend the RNA, the ethanol was removed and the 
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pellet was air-dried. RNase-free water was added to the pellet and the tubes were 
incubated at 55-60
O
C for 10 min.  
 
C) High-Capacity cDNA Reverse Transcription Kit 
 
A 2X reverse transcription (RT) master mix was produced using 2 μl of 10X RT 
Buffer, 0.8 μl 25X dNTP mix, 2 μl 10X RT random primers, 1 μl reverse 
transcriptase, 1 μl RNase inhibitor and 3.2 μl nuclease-free water to make a 
volume of 10 μl. These 10 μl were added to 10 μl of RNA, briefly centrifuged 
and placed in a thermocycler. The reverse transcription reaction involved one 
cycle of a ten minute random primer annealing step at 25
O
C, a 120 minute 
extension step at 37
O
C, a final primer denaturation step at 85
O
C for five seconds 
and a hold step at 4
O
C.  
 
D) Calibrator Normalised Relative Quantification of mRNA 
 
A reaction mix was set up for a 20 μl reactions for the samples and a calibrator 
for the target gene, consisting of 10 μl of 2 X TaqMan® Universal Master Mix, 1 
μl of 20 X TaqMan Gene Expression Assay (containing the primes and probes), 7 
μl of nuclease-free water and 2 μl of cDNA. A reaction mix for the reference 
gene was set up for a 20 μl reaction for the samples and a calibrator, consisting of 
10 μl of 2 X TaqMan® Universal Master Mix, 1 μl of 20 X endogenous control 
assay (containing the primes and probes), 7 μl of nuclease-free water and 2 μl of 
cDNA. 
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Samples were placed in the Applied Biosystems 7500 Real Time PCR System 
and underwent the following reaction: The first hold stage was at 52
O
C for 2 
minutes, followed by a second hold stage at 95
O
C for 10 minutes, and then 40 
cycles of the cycling stage (95
O
C for 15 seconds and 60
O
C for 1 minute), where 
the fluorescence was measure at the end of the 60
O
C step.  
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APPENDIX II: GENOTYPING DATA 
 
 
 Sample # 
 
 
Exon 2 Intron 12 Exon 21 Intron 25 Exon 26 Intron 26 
 
 
Haplotype Pairs
a
  
T-129C C1236T G2677T/A G3050T T5231C C3435T T80C 
 
101 NN CT GG GG TT CC TT TTGGTCT, TCGGTCT 
 
104 NN CT NN GG TC CC TT  
 
105 TC TT GA GG TC CC TT  
 
106 TC TT GG GG TC CC NN  
 
109 TT CC GG GT TC CT TC TCGGCCT, TCGTTTC 
 
110 NN CT GA GG TC CC TT  
 
111 TT CT GG GT CC CT TC  
 
112 TC CT GG NN TT CC TT  
 
113 TC TT GA GT TT CT TC  
 
114 TC CT GA GG CC CC NN  
 
115 TC CT GG GG TC CC TT  
 179 
 
116 NN CT NN GG TC NN NN  
 
117 NN CT NN GG TC CC NN  
 
118 TT TT GG GT TT TT CC TTGGTTC, TTGTTTC 
 
119 TT CT GA GG CC CC NN  
 
120 TT CT GG GT TC CT TC  
 
122 TT TT GG GG TC CC NN TTGGTCT, TTGGCCT 
 
123 TT CT GA GG TC CC TT  
 
124 NN CC NN GG CC CC TT TCGGCCT, TCGGCCT 
 
125 TT TT GA GG TC CC TT  
 
126 TC CT GA GT TC CC TT  
 
127 TC CT GA GG TC CC TT  
 
128 NN CT NN GG TC TT NN  
 
129 NN CT GG GT TT CC TT  
 
130 TT CT GG GT TC CC TT  
 
131 TT CT GG GG TC CC TT  
 180 
 
137 NN NN NN GG TC CC TT  
 
138 NN TT GA GG TT CC NN TTGGTCT, TTAGTCT 
 
139 NN TT NN NN CC CC NN  
 
141 TT TT GG GG TC CC TT TTGGTCT, TTGGCCT 
 
142 TC CT GA GG TC CC TT  
 
143* TT CT GA GT CC NN TT  
 
144* TT CT GG GG TC CC TT  
 
145 TC CT GG GG TC CT TC  
 
146 TT TT GG GG TC CC TT TTGGTCT, TTGGCCT 
 
147 TT CT GG GT TC CT TC  
 
148 TC TT GG GG TT CC TT TTGGTCT, CTGGTCT 
 
149 TT CT GG GT CC CC TT  
 
150 TC TT GA GG CC CC TT  
 
151 TT TT GA GG TC CC TT  
 
153 TC TT GG GG TT CC TT TTGGTCT, CTGGTCT 
 181 
 
154 TT TT GA GG TC CC TT  
 
155 TT TT GA GT CC CC TT  
 
156 TT TT GG GG CC CC TT TTGGCCT, TTGGCCT 
 
157 TT CT GG GG CC CC TT TTGGCCT, TCGGCCT 
 
158 TC TT GG GG TT CC TT TTGGTCT, CTGGTCT 
 
159 TT CT GA GG CC CC TT  
 
160 TC CT GG GG TT CC TT  
 
161 TT TT GG GT TC CC TT TTGGCCT, TTGTTCT 
 
162 NN TT GA NN TT CC TT TTGGTCT, TTAGTCT 
 
163 TT TT GG GT TC CT TC TTGGCCT, TTGTTTC 
 
164 NN TT NN GT TT CC TT TTGGTCT, TTGTTCT 
 
166 NN TT GA GT TT CT TC  
 
167 NN CC NN GT TT CC TT  
 
168 NN NN NN GT TC CC NN  
 
169 TC TT GG GT TT CT TC  
 182 
 
170 TT TT GA GT TT CT TC  
 
171 TT TT GT GG TT CT TC  
 
172 TT CT GA GT TT CC TT  
 
173 NN TT NN GG CC CC TT TTGGCCT, TTGGCCT 
 
175 TT CT GA GG TT TC NN  
 
176 TT CT GG GG TT CC TT TTGGTCT, TCGGTCT 
 
177 NN TT NN GG TC CC TT TTGGTCT, TTGGCCT 
 
178 NN CC GG GG TT CC TT TCGGTCT, TCGGTCT 
 
179 TT CC GG GT TT CC TT TCGGTCT, TCGTTCT 
 
180 TT TT GG GG CC CC TT TTGGCCT, TTGGCCT 
 
181 CC TT GG GG CC CC TT CTGGCCT, CTGGCCT 
 
182 TC TT GG GT TT CT TC  
 
183 TT CC GG GG TC CC TT TCGGTCT, TCGGCCT 
 
184 TC TT GA GT TC CC TT  
 
185 NN TT GG TT NN NN NN  
 183 
 
187 TT TT GG NN TC CC TT TTGGTCT, TTGGCCT 
 
188 CC CT GA GG TC CC TT  
 
189 NN CT GG GG TC CC TT  
 
190 TT CT GG GG TC CC TT  
 
191 TT TT GG GG TT CT TC TTGGTCT, TTGGTTC 
 
192 TT TT GG GG TC CC NN TTGGTCT, TTGGCCT 
 
193 NN CT GG GG CC CC TT TTGGCCT, TCGGCCT 
 
194 CC TT GA GG TC CC TT  
 
195 TT TT GT GG CC CC TT TTGGCCT, TTTGCCT 
 
196 TT CT GG GT TC CC TT  
 
197 TT TT GG GG TT CC TT TTGGTCT, TTGGTCT 
 
198 TC TT GA GG TC CC TT  
 
199 TT TT GT GG TC CC TT  
 
200 TT TT GT GG TC CC TT  
 
201 TC CT GG GT TT CC TT  
 184 
 
203 TT CT TA GT TC CC TT  
 
205 TC TT GA GG CC CC TT  
 
206* TC TT GG GG TC CC TT  
 
207* TT TT GG TT TC CC TT TTGTTCT, TTGTCCT 
 
208* TT CT GA GG TC CT TT  
 
209* TT TT GG GT TT TT TC TTGGTTT, TTGTTTC 
 
210* TT TT GG GG TT CC TT TTGGTCT, TTGGTCT 
 
211* TT TT GG GG TC CC TT TTGGTCT, TTGGCCT 
 
212* TC TT GG GT TT CT TC  
 
213* TT TT GG GG CC CT TT TTGGCCT, TTGGCTT 
 
214* TT TT GG GT TC CT TC TTGGCCT, TTGTTTC 
 
215* TT TT GG GT TC CT TC TTGGCCT, TTGTTTC 
 
216* TT TT GG GG TC CC TT TTGGTCT, TTGGCCT 
 
217* TC CT GG GG TT CC TT TTGGTCT, TTGGCCT 
 
218* TT TT GG GG TC CC TT  
 185 
 
219* TC TT GG GT TC CT TC  
 
222* TT TT GA GG TC CC TT  
 
223* TT CT GA GG TC CC TT  
 
224* TT TT GA GT TC CT TC  
 
225* TT TT GG GT TC CC TT TTGGCCT, TTGTTCT 
 
226* TT TT GG GT TT CT TC TTGGTCT, TTGTTTC 
 
227* TC TT GA GG TC CC TT  
 
228* TT TT GA GG CC CC TT TTGGCCT, TTAGCCT 
 
229* TT CT GG GG TC CC TT  
 
230* TT CT GG GG TT CC TT TTGGTCT, TCGGTCT 
 
231* TT CT GG GT TC CC TT  
 
232* TT CC GG GG TC CC TT TCGGTCT, TCGGCCT 
 
233* TT CC GG GG TT CC TT TCGGTCT, TCGGTCT 
 
234* TT CT GA GG TT CC TT  
 
235* TC CT GG GG TC CC TT  
 186 
 
236* TT CT GG GG TT CC TT TTGGTCT, TCGGTCT 
 
237* CC TT GG GG TC CC TT CTGGTCT, CTGGCCT 
 
238* TT CT GG GG TT CC TT TTGGTCT, TCGGTCT 
 
239* TT CT GG GG CC CC TT TTGGCCT, TCGGCCT 
 
240* TC CT GG GG TC CC TT  
 
241* TC TT GG GG CC CC TT TTGGCCT, CTGGCCT 
 
242* TT CT GG GG TC CC TT  
 
243* TT TT GG GT TC CT TC TTGGCCT, TTGTTTC 
 
244* TT CT GG GG TC CC TT  
 
245* TT CT GG GG TC CC TT  
 
300 TC CC GA GG TC CC TT  
 
301 TC CT GA GG TT CC TC  
 
302 TC TT GA GG TC CC TC  
 
304 TC CC GA GG TT CC TT  
 
305 TC CC GG GG TC CC TT  
 187 
 
307 TT CT GG GG TT CC TC  
 
308 TC CT GG GG TT CC TT  
 
309 TT CC GG GG CC CC TT TCGGCCT, TCGGCCT 
 
310 TT CT GA GG CC CC TT  
 
311 TT TT GG GT TT CT TC TTGGTCT, TTGTTTC 
 
312* NN CT GG GG CC CT TT  
 
313 TT CT GA GG TC CC TT  
 
314 TT CT GA GG CC CT TT  
 
316 TT CC GG GG TC CC TT TCGGTCT, TCGGCCT 
 
317 TT CT GG GG CC CC TT TTGGCCT, TCGGCCT 
 
318 TT CC GG GG TC CC TT TCGGTCT, TCGGCCT 
 
319 TT CT TA GT TC CC TC  
 
320 TC CT GG GG TT CC TT  
 
321 TC CT GA TT TT CT TC  
 
322 TT TT GA TT CC TT TC  
 188 
 
323 TT CT GG GG CC CC TC  
 
324 TT CT GG GG CC CC TC  
 
325 TT CT GG GG TT CC TT TTGGTCT, TCGGTCT 
 
326 TT TT GT TT TT CC TT TTGTTCT, TTTTTCT 
 
327 TT CC GA GG CC CC TT TCGGCCT, TCAGCCT 
 
328 TT CT GT GG TT CC TT  
 
329 TT CT GG GG TC CC TC  
 
330 TT TT GG TT CC CC TT TTGTCCT, TTGTCCT 
 
331 TT CT GG GG TC CC TC  
 
332 TC CT GT GT TC CC TC  
 
333 TT TT GG GT TT CT TT TTGGTCT, TTGTTTT 
 
334 TC CT GG GG TT CC TT  
 
335 TT TT GG GG CC CC TT TTGGCCT, TTGGCCT 
 
336 TC TT GG GG CC CC TT TTGGCCT, CTGGCCT 
 
337 TC CT TA GG TC CC TC  
 189 
 
338 TC CT GA GG TC CC TT  
 
339 TT CT GT GG TC CC TT  
 
340 TC CT TA GG TC CC TT  
 
341 TT CT GA GT TC CT TT  
 
342 TC CT TA GG TC CC TT  
 
343 TT CT GA GG TC CC TC  
 
344 TT CT GG GT TT CC TT  
 
345 TT CT GT GT CC CT TT  
 
346 TT CC GG GG TC CC TT TCGGTCT, TCGGCCT 
 
347 TT CT GA GG CC CC TT  
 
348 TT CT GG GT TT CT TT  
 
349 TT CT GA GG TT CC TT  
 
350 TT CT GG GG TT CC TT TTGGTCT, TCGGTCT 
 
352 TT TT GG GT TT CC TT TTGGTCT, TTGTTCT 
 
353 NN TT GG GT TC CC TT TTGGCCT, TTGTTCT 
 190 
 
354 TT CT GG GG TC CC TT  
 
355 TT CT GG GG CC CC TT TTGGCCT, TCGGCCT 
 
356 TT CT GA GT TT CC TT  
 
358 TT CT GA TT CC CT TT  
 
359 TT CT GG GG TC CC TT  
 
360 TT CT GG GG TC CC TT  
 
361 TT CT GG GG TC CT TC  
 
362 TT CT GG GG CC CC TT TTGGCCT, TCGGCCT 
 
363 TC CT GA GG TC CC TT  
 
364 TT CC GA GG CC CC TT TCGGCCT, TCAGCCT 
 
366 TT CC GG GG TC CC TT TCGGTCT, TCGGCCT 
 
367 TT CT GG GG TC CC TT  
 
368 TT CT GG GG TT CC TT TTGGTCT, TCGGTCT 
 
369 NN CT GG GG CC CC TT TTGGCCT, TCGGCCT 
 
370 NN CC GG GG CC CC TT TCGGCCT, TCGGCCT 
 191 
 
371 TC CT GG GG TC CC TT  
 
372 TT CT GA GG TC CC TT  
 
373 TT CT GG GG TC CT TT  
 
374 TT TT GG GG TT CC TT TTGGTCT, TTGGTCT 
 
375 TC CT GA GG TC CC TT  
 
377 TC CT GG GG TC CT TT  
 
378 CC CT GG GG TT CT TC  
 
379 TT CT GG GT TT CC TC  
 
380 TC TT GG GT TT CC TC  
 
381 TT TT GA GT TT CC TC  
 
382 TT CT GG GG TC CC TC  
 
383 TT CT GG GG CC CC TC  
 
384 TT CC GA GG TC CC TC  
 
385 TT CT GA GG TC CC TT  
 
386 TC TT GA TT TC CT TC  
 192 
 
387 TT CT GA GG TT CC TT  
 
388 TT CT GA GG TC CC TT  
 
389 TT TT GA GG CC CT TT  
 
390 TT TT GG GT TT CC CC TTGGTCC, TTGTTCC 
 
391 NN TT GG GT TT CC TT TTGGTCT, TTGTTCT 
 
392 TC CT GG GG TT CC TT  
 
393 TT CT GA GG TC CC TT  
 
394 TT TT GA GG TT CT TT  
 
395 TT CC GA GG TC CC TT  
 
396 TT TT GA GT TT CT TT  
 
397 NN TT GG NN TT CC TC TTGGTCT, TTGGTCC 
 
398 TT TT GA GT TT CC TT  
 
399 TT CC GG GG TC CT TT  
 
400 NN CT GG GG CC CC TT TTGGCCT, TCGGCCT 
 
401 NN TT GA NN NN CC TT  
 193 
 
402 TT CT GA GG TC CC TT  
 
1000 TT CT GA GG CC CT TC  
 
1001 TT TT GG GG CC CC TT TTGGCCT, TTGGCCT 
 
1002 TT CT GA GG CC CC TT  
 
1003 TT CT GA GT TC CT TT  
 
1008 TT CT GG GG CC CC TT TTGGCCT, TCGGCCT 
 
1011 TT CT GA GG TC CT TT  
 
1019 TT TT GA GG TC TT CC  
 
1021 TT CT GA GG TC CT TC  
 
1023 TC CC GG GG CC CC TT TCGGCCT, CCGGCCT 
 
1025 TT CC GG GG CC CC TT TCGGCCT, TCGGCCT 
 
1027 CC CT GG GG CC CC TT CTGGCCT, CCGGCCT 
 
1033 TT CT GA GG TT CC TT  
 
1034 TT TT GA GG TT CT TC  
 
1035 TC TT GA GT TT CC TT  
 194 
 
1036 TC TT GG GG CC CC TT TTGGCCT, CTGGCCT 
 
1038 TT TT GG GG TT CC TT TTGGTCT, TTGGTCT 
 
1040 TT TT GA GG CC CC TT TTGGCCT, TTAGCCT 
 
1046 TC TT GG GG TC CC TT  
 
1047 TT TT GG GG TC CC TT TTGGTCT, TTGGCCT 
 
1049 TT TT GA GG TC CC TT  
 
1050 TT TT GG GG CC CT TT TTGGCCT, TTGGCTT 
 
1051 TT CT GA GT CC CC TT  
 
1053 TC TT GA GG CC CC TT  
 
1056 TC CT GA GG TC CC TT  
 
1057 TT TT GA GG CC CC TT TTGGCCT, TTAGCCT 
 
1058 TT CT GA GG TC CC TT  
 
1062 TC CC GA GG TT CC TT  
 
1064 TT TT GA GG TC CT TC  
 
1065 TT CT GA GG CC CC TT  
 195 
 
1066 TT TT GA GT CC CC TT  
 
1067 TT TT GA GG TC CT TT  
 
1068 TT TT GA GG CC CC TT TTGGCCT, TTAGCCT 
 
1072 TT TT GA GG CC CC TT TTGGCCT, TTAGCCT 
 
1073 TT TT GA GG TT CT TC  
 
1074 TT TT GA GG CC CT TC  
 
1075 TT TT GA GG CC CC TT TTGGCCT, TTAGCCT 
 
1076 NN TT GG GT TC CT TC  
 
1079 TC NN GG NN NN CC TT  
 
1080 TC CC GG GG CC CC TT TCGGCCT, CCGGCCT 
 
1081 TC TT GG GG TC CC TT  
 
1084 TT TT GA GG CC CC TT TTGGCCT, TTAGCCT 
 
1086 TC TT GA GG CC CC TT  
 
1087 TC CT GG GG CC CC TT  
 
1089 TT TT GA GG TC CC TT  
 196 
 
1091 TT TT GA GG TC CC TT  
 
1092 TT TT GA GG CC CC TT TTGGCCT, TTAGCCT 
 
1094 TT TT GG GG TC CC TT TTGGTCT, TTGGCCT 
 
1097 TC TT TA GG TC CC TT  
 
1098 TT TT GA GG CC CC TT TTGGCCT, TTAGCCT 
 
1100 TC CT GG GG TC CC TT  
 
1102 TT TT TA GG TT CT TC  
 
1103 TT CT GG GG TC CT TC  
 
1104 TT TT GA GG TC CC TT  
 
1105 TT CT GA GG CC CC TT  
 
1106 TT TT GA GG CC CC TT TTGGCCT, TTAGCCT 
 
1108 TC TT GA GT TT CC TT  
 
1109 TC TT GA GT TT CT TC  
 
1111 TT TT GG GG TC CC TT TTGGTCT, TTGGCCT 
 
1112 TT TT GA GG CC CC TT TTGGCCT, TTAGCCT 
 197 
 
1115 TT TT GG GG TC CC TT TTGGTCT, TTGGCCT 
 
1117 TC TT GG GG TT CC TT TTGGTCT, CTGGTCT 
 
1119 TC TT GA GG TT CC TT  
 
1121 TT TT GG TT TT CT TC TTGTTCT, TTGTTTC 
 
1122 TT CC GG GG TT CC TT TCGGTCT, TCGGTCT 
 
1124 TT TT GA GG TC CC TT  
 
1125 TC TT GG GG CC CC TT TTGGCCT, CTGGCCT 
 
1129 TC TT GG GG CC CC TT TTGGCCT, CTGGCCT 
 
1131 TC CT GG GG TC CC TT  
 
1132 TC CT GG GG CC NN NN  
 
1134 TT TT GG GG TC CC TT TTGGTCT, TTGGCCT 
 
1136 TT CT GG GG CC CC TT TTGGCCT, TCGGCCT 
 
1137 TT TT GG GG CC CC TT TTGGCCT, TTGGCCT 
 
1139 TC TT GG GG CC CC TT TTGGCCT, CTGGCCT 
 
1140 TC TT GG GG CC CC TT TTGGCCT, CTGGCCT 
 198 
 
1141 TT TT GG GG TC CT TT  
 
1142 TC TT GG GG TC CC TT  
 
1143 TT CC GG GG TT CC TT TCGGTCT, TCGGTCT 
 
1146 TC CT GG GG CC CC TC  
 
1150 TC TT GA GG TC CC TT  
 
1151 TC TT GG GG CC CC TT TTGGCCT, CTGGCCT 
 
1153 TT TT GG GG TT CC TT TTGGTCT, TTGGTCT 
 
1155 TT TT GA GG TC CC TT  
 
1156 TC CC GG NN CC CC TT TCGGCCT, CCGGCCT 
 
1157 TC CT GG GG CC NN NN  
 
1158 TC TT GG GG CC CT TC  
 
1161 TC CT GA GG TT CC TT  
 
1162 TT CT GG GG TT CC TT TTGGTCT, TCGGTCT 
 
1165 TT TT GA GG TC CC TT  
 
1166 TT CC GA GG TT CC TT TCGGTCT, TCAGTCT 
 199 
 
1168 TT TT GA GG CC CC TT TTGGCCT, TTAGCCT 
 
1169 TC CC GA GG TC CC TT  
 
1173 TT CC GG GG TC CC TT TCGGTCT, TCGGCCT 
 
1174 TT CT GA GG TT CC TT  
 
1175 TC TT GG GG CC CC TT TTGGCCT, CTGGCCT 
 
1176 TT TT GG GG CC CC TT TTGGCCT, TTGGCCT 
 
1178 TT TT GG GG TT CC TT TTGGTCT, TTGGTCT 
 
1179 TT TT GG GG TT CC TT TTGGTCT, TTGGTCT 
 
1180 TT TT GA GT TC CT TC  
 
1182 TC TT GA GG TT CC TT  
 
1184 TT CT GG GG TC CC TT  
 
1185 TC TT GG GT TT CT TT  
 
1187 TT CT GA GG TT CC TT  
 
1188 TC TT GA GG TC CT TT  
 
1191 TC TT GG GT TC CT TC  
 200 
 
525-00002-8 TT CT GG NN TC NN TT  
 
525-00016-0 TT TT GG GT TC CC TT  
 
525-00017-1 NN TT GG GT TT CC TT TTGGTCT, TTGTTCT 
 
525-00029-8 TC CC GA GT TT NN NN  
 
525-00030-1 TC TT GG GG TT NN TT TTGGTCT, CTGGTCT 
 
525-00031-6 TT TT GG GG TT CC TC TTGGTCT, TTGGTCC 
 
525-00032-7 TT CT GT TT TT CC TT  
 
525-00034-3 TT CT GG GG TC CC TT  
 
536-00001-5 TT CT GG GG TC CC TT  
 
536-00003-1 TT TT GA GG TC CC NN  
 
536-00010-7 TT CT GG GT TC TC NN  
 
536-00012-1 NN CT GG NN CC CC NN TTGGCCT, TCGGCCT 
 
536-00014-9 TT CT GA GG TC NN TT  
 
536-00017-3 TT CT GG GG TC CC TT  
 
541-00003-6 TT TT GG GG TC CC TT TTGGTCT, TTGGCCT 
 201 
 
541-00004-9 TT TT GG GG TC TC TC TTGGTTC, TTGGCCT 
 
541-00006-2 TT CT GA GG CC CC TT  
 
541-00008-5 NN TT GG NN TT NN NN  
 
541-00009-8 TT TT GA GT TC CC TT  
 
541-00011-5 TT TT GA GG CC CC TT TTGGCCT, TTAGCCT 
 
541-00013-1 TT TT GA GG TC TC TT  
 
541-00014-4 TT TT GA GG TC TC TT  
 
541-00017-8 TT CT GG GG TC TC TT  
 
541-00018-0 TT CT GG GT TC CC TT  
 
541-00019-3 TT CT GG GG TC CC TC  
 
541-00022-8 TT TT GT GT TC TC TC  
 
541-00023-4 TT TT GG GT TC NN NN  
 
541-00024-2 TT TT GG GG TC CC NN TTGGTCT, TTGGCCT 
 
541-00025-6 TT TT GG GT TC TT NN  
 
541-00035-3 TT TT GG GG TC NN TT TTGGTCT, TTGGCCT 
 202 
 
615-000-015 TT CT GG GG TC CC TT  
 
615-00002-6 TT CT GG GG TT CC TT TTGGTCT, TCGGTCT 
 
615-00003-1 TT TT GG GG TT CC TT TTGGTCT, TTGGTCT 
 
615-00004-4 TT CT GG GG TC TC TC  
 
615-00005-9 TT CT GG GT TC TC TC  
 
615-00006-7 TT TT GG TT TC CC NN TTGTTCT, TTGTCCT 
 
615-000-078 TT TT GG GG TC CC TT TTGGTCT, TTGGCCT 
 
615-00008-0 TT CT GA GT TC CC TT  
 
615-00009-3 TC CT GG GT TC CC TT  
 
615-00010-7 TT TT GT GT TC TC TC  
 
615-00011-0 TT TT GG GG TC TC TC TTGGTTC, TTGGCCT 
 
615-00012-1 TT TT GG GG TC CC TT TTGGTCT, TTGGCCT 
 
615-00013-6 TT TT GG GG CC CC TT TTGGCCT, TTGGCCT 
 
615-00032-5 TT TT GG GG TC TC TC TTGGTTC, TTGGCCT 
 
615-00033-2 TT TT TA GT TC TC TC  
 203 
 
615-00034-0 TT TT GG GG TT CC TT TTGGTCT, TTGGTCT 
 
615-00035-8 TT TT GG GG TT CC TC TTGGTCT, TTGGTCC 
 
615-00036-6 TT CT GA NN TC CC TT  
 
615-000-377 TT TT TT TT TC TC TC TTTTTTC, TTTTCCT 
 
615-00038-1 TT TT GA GG TC CC TT  
 
615-00039-4 TT CT GG NN TC TC TC  
 
615-00040-6 TT TT TA GT TC TC TC  
 
616-00001-7 TT CT TA GG TC CC TT  
 
616-000-042 TT TT GA GG TC CC TT  
 
616-00009-1 TT CT GA GG TC NN NN  
 
616-00044-5 TT CT GG GG TC CC TT  
 
616-00045-3 TC CT GG NN TT CC TT  
 
616-00045-7 TT TT GG GG TT TC TT TTGGTCT, TTCCTTT 
 
616-00047-2 TC TT GA GT TC TC NN  
 
616-00048-6 TC TT GA GG TC CC TT  
 204 
 
616-000-499 TT TT TA GG CC CC TT TTAGCCT, TTTGCCT 
 
616-00050-3 TT CT GG GG TC CC TT  
 
 
Key:  
NN No data   
a Only unambiguous haplotypes are shown. No haplotype indicated where PHASE could not resolve the haplotype.   
* General Population samples 
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APPENDIX III: CALIBRATOR NORMLIZED RELATIVE QUANTITATIVE PCR DATA 
Sample Ct 1 Ct 2 Ct 3 Ct 4 Ct 5 Ave Ct SD ΔCt SD ΔΔCt SD RQ 
RQ 
Min 
RQ 
Max 
1036T 32.84 33.02 32.78 32.65 32.93 32.85 0.14 12.79 1.01 2.14 1.01 0.23 0.46 0.11 
1036R 21.09 21.21 19.34 19.23 19.39 20.05 1.00        
1038T 32.31 31.92 31.61 31.86 31.98 31.94 0.25 11.36 0.45 0.70 0.45 0.61 0.84 0.45 
1038R 20.80 20.54 20.55 21.00 19.99 20.58 0.38        
1057T 30.48 30.66 30.84 31.20 30.49 30.73 0.30 10.90 0.69 0.24 0.69 0.85 1.36 0.52 
1057R 20.41 20.59 19.43 19.19 19.56 19.84 0.62        
1066T 34.62 35.25 33.86 34.24 33.74 34.34 0.61 11.71 0.86 1.06 0.86 0.48 0.87 0.26 
1066R 23.48 22.64 21.87 22.29 22.85 22.63 0.60        
1081T 33.15 32.90 32.62 32.84 33.14 32.93 0.22 11.90 0.38 1.25 0.38 0.42 0.55 0.32 
1081R 21.44 21.21 20.68 21.04 20.77 21.03 0.31        
1087T 34.64 34.24 34.85 33.60 33.81 34.23 0.53 12.74 0.82 2.09 0.82 0.24 0.41 0.13 
 206 
1087R 22.13 22.18 21.12 21.07 20.91 21.48 0.62        
1106T 34.26 34.93 33.40 34.15 34.19 34.18 0.54 12.16 0.77 1.51 0.77 0.35 0.60 0.21 
1106R 22.31 22.68 21.95 21.98 21.19 22.02 0.55        
1129T 33.68 33.85 32.61 32.94 32.85 33.19 0.55 12.38 0.89 1.73 0.89 0.30 0.56 0.16 
1129R 21.77 21.24 20.16 20.67 20.18 20.80 0.70        
1137T 32.39 31.72 31.57 31.85 31.24 31.75 0.42 10.71 0.8 0.06 0.8 0.96 1.67 0.55 
1137R 21.93 21.39 21.01 20.71 20.14 21.04 0.68        
1141T 33.83 34.10 34.55 33.37 33.48 33.87 0.48 12.67 0.75 2.02 0.75 0.25 0.42 0.15 
1141R 21.40 22.05 20.95 20.51 21.06 21.20 0.57        
1150T 34.62 33.18 33.59  34.17 33.89 0.64 12.09 1.09 1.43 1.09 0.37 0.79 0.17 
1150R 23.27 21.93 21.01 21.40 21.39 21.80 0.88        
1153T 32.01 31.44 31.25 31.32 31.53 31.51 0.30 11.21 0.73 0.56 0.73 0.68 1.13 0.41 
1153R 21.08 20.92 19.50 20.05 19.96 20.30 0.67        
 207 
1156T 31.32 31.07 31.04 30.77 30.98 31.04 0.20 10.58 0.39 -0.07 0.39 1.05 1.38 0.80 
1156R 20.09 20.16 20.65 20.88 20.50 20.45 0.33        
1158T 33.12 32.82 32.61 32.66 32.70 32.78 0.20 10.87 0.32 0.22 0.32 0.86 1.07 0.69 
1158R 22.17 21.75 21.64 21.79 22.18 21.91 0.25        
1169T 32.06 32.04 31.74 32.02 32.02 31.98 0.13 10.89 0.28 0.23 0.28 0.85 1.03 0.70 
1169R 21.26 20.88 20.89 20.98 21.44 21.09 0.25        
1173T 31.93 31.25 31.53 31.76 31.84 31.66 0.28 11.02 0.59 0.36 0.59 0.78 1.17 0.52 
1173R 20.36 19.92 20.78 20.92 21.25 20.65 0.52        
1174T 34.94 34.45 34.21 34.69 34.90 34.64 0.31 11.40 0.74 0.75 0.74 0.59 0.99 0.36 
1174R 22.44 23.92 22.63 23.38 23.80 23.23 0.67        
1175T 36.96 34.61 33.24 34.25 34.43 34.70 1.37 11.93 1.39 1.27 1.39 0.41 1.08 0.16 
1175R 22.55 22.96 22.74 22.77 22.84 22.77 0.15        
1176T 33.02 32.93 32.62 32.88 32.91 32.87 0.15 11.14 0.28 0.48 0.28 0.71 0.87 0.59 
 208 
1176R 21.70 21.50 21.61 21.73 22.13 21.73 0.24        
1178T 30.58 30.25 30.37 30.41 30.43 30.41 0.12 10.15 0.32 -0.51 0.32 1.42 1.77 1.14 
1178R 20.70 19.93 20.02 20.31 20.32 20.26 0.30        
1179T 35.46 34.95 34.53 34.91 35.40 35.05 0.38 12.96 0.48 2.31 0.48 0.20 0.28 0.14 
1179R 22.48 22.12 21.72 21.89 22.23 22.09 0.30        
1180T 31.92 31.25 30.83 30.96 30.96 31.18 0.44 9.93 1.08 -0.73 1.08 1.66 3.50 0.78 
1180R 21.17 22.92 20.37 20.62 21.21 21.26 0.99        
1182T 31.89 31.95 31.87 31.93 32.33 31.99 0.19 10.87 0.33 0.22 0.33 0.86 1.08 0.69 
1182R 21.44 20.99 20.87 20.94 21.39 21.12 0.27        
1184T 30.35 30.65 30.27 30.51 30.72 30.50 0.19 10.87 0.22 0.21 0.22 0.86 1.01 0.74 
1184R 19.59 19.50 19.62 19.63 19.83 19.63 0.12        
1185T 32.07 31.62 31.51 31.60 31.82 31.72 0.22 10.44 0.28 -0.21 0.28 1.16 1.41 0.95 
1185R 21.36 21.16 21.05 21.46 21.38 21.28 0.17        
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1191T 33.91 33.85 31.50 33.55 33.56 33.28 1.01 10.68 1.04 0.03 1.04 0.98 2.02 0.48 
1191R 22.29 22.89 22.46 22.54 22.79 22.59 0.25        
CalibratorT 30.13 30.15 30.11 30.15 30.26 30.16 0.06 10.66 0.48 0.00 0.48 1.00   
CalibratorR 20.27 19.04 19.23 19.35 19.65 19.51 0.48        
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APPENDIX IV: ETHICS CLEARANCE CERTIFICATE FOR 2006 AND 
2009 COLLECTIONS 
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APPENDIX V: PERMISSION LETTER FROM HELEN JOSEPH 
HOSPITAL TO CONDUCT SAMPLE COLLECTION IN 2009 
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APPENDIX VI: PATIENT INFORMATION AND CONSENT FORM FOR  
THE 2006 AND 2009 COLLECTIONS 
PATIENT INFORMATION & CONSENT FORM 2006 
 
“Population Genetics of HIV resistance in southern Africa” 
 
 
________________________________________________________________ 
 
PATIENT NUMBER _____________ 
 
Dear Patient, 
 
We, in the Departments of Molecular and Cell Biology and the Clinical HIV 
Research Unit at the University of the Witwatersrand want to gain a better 
understanding of the variation in people’s responses to HIV and AIDS.  Some 
people in other parts of the world have genes that make them respond to HIV in 
different ways.  We want to examine variation in these genes in people of 
southern African origin.   Your blood and your medical history will allow us to 
determine what genetic variation is common and what effects that variation has 
on how fast HIV positive people become sick with AIDS.  
 
We would be very grateful if you would donate 5 ml (1 tsp) of blood, drawn from 
an arm vein only once.  Slight discomfort may be associated with drawing blood; 
this may include pain, swelling or bruising at the site of puncture.   We also ask 
that you allow us to have access to your medical records at this clinic.   
 
POTENTIAL BENEFITS 
There will be no immediate benefit to you by participating in this study.   You will 
be assisting in collecting accurate information about patients infected with HIV.  
We hope the data will help us to assess long term trends and design effective 
treatments for people in southern Africa. 
 
VOLUNTARY PARTICIPATION 
You may choose to take part in this study and you may decide to withdraw from 
the study at any time. 
 
PRIVACY 
We will keep your records confidential. Your blood samples are encoded with a 
number and your identity will only be known to the principal investigator and your 
doctor. 
 
COST OF PARTICIPATION 
There will be no charge for the laboratory tests or procedures which are required 
for your participation in the study.  The study institution (University of the 
Witwatersrand, School of Molecular and Cell Biology) may compensate you for 
any travel expenses incurred by you to attend the clinic up to R20.  There is no 
other form of compensation for your participation. 
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CONTACT NUMBERS 
 
The investigator in charge of this study is Prof Tracy McLellan who may be 
reached for answers to questions concerning this study at 011 717-6357. 
 
If you have questions about patient rights, you may contact The Committee for 
Research on Human Subjects, telephone (011) 717-1234. 
 
If there is an emergency, you may contact the doctor, Dr P MacPhail, at 278-
8800. 
 
CONSENT 
 
I, _____________________________ have voluntarily agreed to take part in this 
research study.  I have read this consent form (or had it read to me by the social 
worker) and have had an opportunity to discuss this with my doctor.  All 
questions have been answered to my satisfaction and I fully understand my 
participation in this study.  I will be given a copy of this consent form to keep. 
 
 
 
 
__________________________________   ______________   ___________ 
Signature of Patient                                        Date                        Time 
 
 
 
__________________________________   ______________   ___________ 
Signature of Witness                                       Date                        Time 
 
 
 
__________________________________   ______________   ___________ 
Signature of Investigator                                Date                        Time 
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PATIENT INFORMATION AND CONSENT FORM 2009 
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APPENDIX VII: PATIENT QUESTIONNAIRE FOR THE 2006 AND 2009 
COLLECTIONS 
PATIENT QUESTIONNAIRE 2006 
 
“Population Genetics of HIV Resistance in Southern Africa” 
 
Patient Number _______________________  File number _______________________________ 
 
We need information about you and your relatives in order to determine if subpopulations differ 
from each other.  Please try to be as accurate as possible.  It is better to leave out information than 
to give us something that might be wrong. 
 
YOU 
Place of birth _____________________Province or country____________________ 
 
Home language _____________________ 
 
 
YOUR PARENTS 
Your mother     Your father 
Place of birth _______________________________  Place of birth ________________________ 
 
Province or country __________________________ Province or country__________________ 
 
Home language _____________________________   Home language  _____________________ 
 
 
YOUR GRANDPARENTS 
Your mother’s mother    Your father’s mother 
Place of birth _______________________________ Place of birth ________________________ 
 
Province or country __________________________ Province or country___________________ 
 
Home language _____________________________ Home language ______________________ 
 
 
Your mother’s father    Your father’s father 
Place of birth _______________________________ Place of birth ________________________ 
 
Province or country__________________________   Province or country___________________ 
 
Home language _____________________________ Home language ______________________ 
 
MEDICAL INFORMATION 
 
Year of birth _______________________________ 
 
HIV + since _______________________________ 
 
Most recent CD4+ count ______________________ Date _______________________________ 
 
Other conditions: ________________________________________________________________ 
 
Tuberculosis?___________________________________________________________________ 
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PATIENT QUESTIONNAIRE 2009  
 
 221 
 
 
 
 222 
 
 
 
 223 
APPENDIX VIII: ETHICS CLEARANCE CERTIFICATE FOR USE OF 
THE DATABASE 
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APPENDIX IX: PERMISSION LETTER FROM HELEN JOSEPH 
HOSPITAL FOR USE OF THE DATABASE 
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APPENDIX X: SOP FOR RESEARCH AT THEMBA LETHU CLINIC 
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